var title_f6_3_6192="Knee MCL stress XR";
var content_f6_3_6192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stress radiograph revealing Grade 3 MCL tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stress radiograph revealing gross medial joint line opening indicating complete tears of the medial collateral, anterior, and posterior cruciate ligaments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bucholz, RW, Heckman, JD. Rockwood &amp; Green's Fractures in Adults, Fifth Edition. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6192=[""].join("\n");
var outline_f6_3_6192=null;
var title_f6_3_6193="Fluindione: International drug information";
var content_f6_3_6193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluindione: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Previscan (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4145741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticoagulant, Indanedione",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4145742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders in connection with certain fibrillations, mitral valvulopathies, valvular prosthesis, myocardial infarctions, hip surgery, or catheter placement",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4145744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 20 mg once daily; maintenance: Adjust according to coagulation (INR) monitoring",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4145745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10450 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6193=[""].join("\n");
var outline_f6_3_6193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302625\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145741\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145742\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145744\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821169\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145745\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10450|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6194="Autosomal recessive inheritance";
var content_f6_3_6194=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Recessive inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6194=[""].join("\n");
var outline_f6_3_6194=null;
var title_f6_3_6195="Multiple vitamins (pediatric): Drug information";
var content_f6_3_6195=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Multiple vitamins (pediatric): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ADEKs&reg; [OTC];",
"     </li>",
"     <li>",
"      AquADEKs&trade; [OTC];",
"     </li>",
"     <li>",
"      Centrum Kids&reg; [OTC];",
"     </li>",
"     <li>",
"      Flintstones&trade; Complete [OTC];",
"     </li>",
"     <li>",
"      Flintstones&trade; Gummies [OTC];",
"     </li>",
"     <li>",
"      Flintstones&trade; Plus Bone Building Support Gummies [OTC];",
"     </li>",
"     <li>",
"      Flintstones&trade; Plus Bone Building Support [OTC];",
"     </li>",
"     <li>",
"      Flintstones&trade; Plus Immunity Support Gummies [OTC];",
"     </li>",
"     <li>",
"      Flintstones&trade; Plus Immunity Support [OTC];",
"     </li>",
"     <li>",
"      Flintstones&trade; Plus Iron [OTC];",
"     </li>",
"     <li>",
"      Flintstones&trade; Sour Gummies [OTC];",
"     </li>",
"     <li>",
"      My First Flintstones&trade; [OTC];",
"     </li>",
"     <li>",
"      MyKidz Iron FL&trade;;",
"     </li>",
"     <li>",
"      MyKidz Iron&trade; [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Kids Jolly Rancher&trade; Gummies [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Kids Jolly Rancher&trade; Sour Gummies [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Kids Scooby-Doo!&trade; Complete [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Kids Scooby-Doo!&trade; Gummies [OTC];",
"     </li>",
"     <li>",
"      Poly-Vi-Sol&reg; With Iron [OTC];",
"     </li>",
"     <li>",
"      Poly-Vi-Sol&reg; [OTC];",
"     </li>",
"     <li>",
"      SourceCF&reg; [OTC];",
"     </li>",
"     <li>",
"      Tri-Vi-Sol&reg; With Iron [OTC];",
"     </li>",
"     <li>",
"      Tri-Vi-Sol&reg; [OTC];",
"     </li>",
"     <li>",
"      Vitalets [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Daily dose varies by product; refer to package insert for specific product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Content varies depending on product used. For more detailed information on ingredients in these and other multivitamins, please refer to",
"     <b>",
"      Multivitamin Product",
"     </b>",
"     comparison table.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer with food to decrease stomach upset. Chewable tablets may be crushed and mixed with food. Oral drops may be mixed with cereal, fruit juice, or food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention/treatment of vitamin deficiency; products containing fluoride are used to prevent dental caries; labeled for OTC use as a dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual vitamin monographs.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; pre-existing hypervitaminosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iron toxicity: Severe iron toxicity may occur in overdose, particularly when ingested by children; iron is a leading cause of fatal poisoning in children; store out of children's reach and in child-resistant containers. Adult preparations may contain amounts of iron which should not be used in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not all products can be used in children of all age groups; consult specific product labeling prior to use. Do not exceed recommended doses.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F234648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Iron absorption is inhibited by eggs and milk.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14191359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual vitamin monographs for requirements during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14191360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual vitamin monographs for requirements while breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F234645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take with food to decrease stomach upset. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F234644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Centrum Kids Complete Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (80): $7.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Flintstones Complete Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (60): $7.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Flintstones Gummies Bone Build Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (50): $7.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Flintstones/My First Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     with C &amp; FA (60): $5.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Land Before Time Multivitamin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     w/Extra C &amp; FA (60): $5.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $5.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (MVC-Fluoride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (90): $35.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (90): $35.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (90): $35.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Poly-Vi-Flor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (30): $225.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (30): $225.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $225.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Poly-Vi-Flor/Iron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-10 mg (30): $225.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Sea Buddies Daily Multiple Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (60): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tri-Vi-Sol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500-400-35 (50 mL): $7.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tri-Vi-Sol/Iron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (50 mL): $7.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tri-Vita Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500-400-35 unit-mg/mL (50 mL): $8.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Poly-Vi-Flor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/mL (50 mL): $225.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Poly-Vi-Flor/Iron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-7 mg/mL (50 mL): $225.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Tri-Vi-Flor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/mL (50 mL): $225.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/mL (50 mL): $225.98",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10316 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6195=[""].join("\n");
var outline_f6_3_6195=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234649\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234655\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234652\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234638\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234628\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234641\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234639\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234653\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234643\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234631\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234648\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14191359\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14191360\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234645\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234644\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10316|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6196="Verteporfin: Patient drug information";
var content_f6_3_6196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Verteporfin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33060?source=see_link\">",
"     see \"Verteporfin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13164018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Visudyne&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Visudyne&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691949",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat macular degeneration.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703127",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to verteporfin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Wear clothing and eyewear that protects you from the sun for 5 days after care. Sunscreens will not protect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694198",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A laser is needed to make this drug work.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11458 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-293D88DB16-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6196=[""].join("\n");
var outline_f6_3_6196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164018\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233956\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016202\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016201\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016206\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016207\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016209\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016204\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016205\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016210\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016211\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33060?source=related_link\">",
"      Verteporfin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6197="Brompheniramine and phenylephrine: Patient drug information";
var content_f6_3_6197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Brompheniramine and phenylephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32067?source=see_link\">",
"     see \"Brompheniramine and phenylephrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7675109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BroveX&trade; PEB [OTC];",
"     </li>",
"     <li>",
"      Dimaphen&trade; Children's Cold &amp; Allergy [OTC];",
"     </li>",
"     <li>",
"      Dimetapp&reg; Children's Cold &amp; Allergy [OTC];",
"     </li>",
"     <li>",
"      Entre-B [OTC];",
"     </li>",
"     <li>",
"      LoHist PEB [OTC];",
"     </li>",
"     <li>",
"      Rynex PE;",
"     </li>",
"     <li>",
"      Vazobid-PD&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to brompheniramine, phenylephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, glaucoma, very bad heart disease, trouble passing urine, ulcer disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12107 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-447D2A5374-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6197=[""].join("\n");
var outline_f6_3_6197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7675109\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015807\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015809\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015808\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015813\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015814\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015816\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015811\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015812\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015817\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015818\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32067?source=related_link\">",
"      Brompheniramine and phenylephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6198="Oxycodone: Patient drug information";
var content_f6_3_6198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxycodone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     see \"Oxycodone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=see_link\">",
"     see \"Oxycodone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxecta&trade;;",
"     </li>",
"     <li>",
"      OxyCONTIN&reg;;",
"     </li>",
"     <li>",
"      Roxicodone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxycodone CR;",
"     </li>",
"     <li>",
"      CO Oxycodone CR;",
"     </li>",
"     <li>",
"      Oxy.IR&reg;;",
"     </li>",
"     <li>",
"      OxyContin&reg;;",
"     </li>",
"     <li>",
"      OxyNEO&trade;;",
"     </li>",
"     <li>",
"      PMS-Oxycodone;",
"     </li>",
"     <li>",
"      PMS-Oxycodone CR;",
"     </li>",
"     <li>",
"      Supeudol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely to make sure you do not misuse, abuse, or become addicted to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3689402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew or crush tablets. Very bad effects may happen if you inject or take chewed or crushed long-acting tablets. Do not use for fast pain relief or on an as needed basis. Your breathing may be slowed down too much when using these products. Keep away from children. Accidental exposure may cause death.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705481",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4031865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take the 20 mg/mL oral liquid if you are not already taking higher doses of opioids. Keep away from children, can cause deadly overdose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxycodone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2738709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad asthma, bowel block, or lung disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some products of oxycodone are in a wax matrix; you may see this in your stool. The oxycodone has been taken into the body, but the wax has not.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2807748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There are 2 liquids. Make sure you have the right one.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble swallowing, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3558884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Oxecta&trade;: Swallow the tablet whole with lots of water right after putting it in your mouth. Do not crush, wet or melt the tablet before putting it in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10939 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6198=[""].join("\n");
var outline_f6_3_6198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204904\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023445\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023447\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023446\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023451\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023452\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023454\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023449\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023450\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023455\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023456\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=related_link\">",
"      Oxycodone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=related_link\">",
"      Oxycodone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6199="Approach to the child with knock-knees";
var content_f6_3_6199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with knock-knees",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6199/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6199/contributors\">",
"     Scott B Rosenfeld, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6199/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6199/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6199/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6199/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6199/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/3/6199/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knock-knees (genu valgum) is an angular deformity at the knee where the apex of the deformity points toward the midline (",
"    <a class=\"graphic graphic_figure graphicRef62835 \" href=\"UTD.htm?42/25/43408\">",
"     figure 1",
"    </a>",
"    ). Bow-legs (genu varum) are an angular deformity at the knee where the apex of the deformity points away from the midline.",
"   </p>",
"   <p>",
"    Bow-legs and knock-knees are among the most common musculoskeletal anatomic variations encountered by pediatric primary care providers and a common reason for referral to a pediatric orthopedic surgeon. However, most children with knock-knees or bow-legs have variations of normal lower-extremity development and can be monitored by the primary care provider.",
"   </p>",
"   <p>",
"    An understanding of the normal physiologic development of the lower extremity is essential in differentiating physiologic from pathologic alignment. Pathologic causes of knock-knees include posttraumatic (eg, Cozen fracture), rickets (eg, renal osteodystrophy), skeletal dysplasias, mucopolysaccharidosis, and neoplasms. Unlike physiologic knock-knees, these conditions generally do not improve over time and may require treatment with bracing or surgery.",
"   </p>",
"   <p>",
"    This topic will provide an overview of normal physiologic alignment of the lower extremity, physiologic and pathologic causes of knock-knees, and an approach to the child with knock knees. Bow-legs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27511?source=see_link\">",
"     \"Approach to the child with bow-legs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL PHYSIOLOGIC ALIGNMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of normal physiologic development of the lower extremity is essential to differentiation of physiologic from pathologic deformities. Lower-extremity alignment goes through a predictable progression from varus (bow-legs) to valgus (knock-knees) over the first seven years of life (",
"    <a class=\"graphic graphic_figure graphicRef74063 \" href=\"UTD.htm?37/33/38417\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53765 \" href=\"UTD.htm?38/10/39085\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/1\">",
"     1",
"    </a>",
"    ]. There is a wide range of normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At birth, normal alignment is varus.",
"     </li>",
"     <li>",
"      As the child begins to stand and walk, the amount of varus often increases. Children who walk at an early age may have greater varus alignment.",
"     </li>",
"     <li>",
"      Around 18 to 24 months of age, alignment should be neutral.",
"     </li>",
"     <li>",
"      After 24 months, alignment should progress to valgus until it reaches a maximum at four years.",
"     </li>",
"     <li>",
"      After age four years, valgus alignment should decrease toward physiologic adult alignment of slight valgus to neutral.",
"     </li>",
"     <li>",
"      By age seven years, a child usually has reached his or her adult lower-extremity alignment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES OF KNOCK-KNEES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of genu valgum include physiologic valgus, posttraumatic (eg, Cozen fracture),",
"    <span class=\"nowrap\">",
"     systemic/metabolic",
"    </span>",
"    conditions (eg, rickets, mucopolysaccharidosis type IV), skeletal dysplasias (eg, chondroectodermal dysplasia) and neoplasms (eg, multiple hereditary exostoses) (",
"    <a class=\"graphic graphic_table graphicRef71973 \" href=\"UTD.htm?14/46/15085\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Osteochondroma and hereditary multiple osteochondromas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physiologic valgus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genu valgum is part of normal development between two and five years (",
"    <a class=\"graphic graphic_figure graphicRef74063 \" href=\"UTD.htm?37/33/38417\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53765 \" href=\"UTD.htm?38/10/39085\">",
"     figure 3",
"    </a>",
"    ). In physiologic valgus, the tibiofemoral angle is within two standard deviations of the mean for age. Maximal physiologic valgus is usually reached by age four or five years. Spontaneous correction occurs during the next few years until the child reaches the adult alignment of slight valgus to neutral.",
"   </p>",
"   <p>",
"    Characteristic features of physiologic valgus include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age between two and five years",
"     </li>",
"     <li>",
"      Symmetric valgus deformities",
"     </li>",
"     <li>",
"      Normal stature",
"     </li>",
"     <li>",
"      Lack of symptoms, although in severe cases the child may have difficulty running or complain of anterior knee pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flat feet and external tibial torsion may accompany physiologic valgus and can accentuate its appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathologic valgus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic valgus may occur after trauma, in association with a number of",
"    <span class=\"nowrap\">",
"     systemic/metabolic",
"    </span>",
"    conditions, skeletal dysplasia, or neoplasms (",
"    <a class=\"graphic graphic_table graphicRef71973 \" href=\"UTD.htm?14/46/15085\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinical and radiographic features help to distinguish physiologic from pathologic valgus. Clues to pathologic valgus include age &lt;2 years or &gt;7 years, short stature, medial thrust asymmetry, and progression rather than improvement after four to five years of age (",
"    <a class=\"graphic graphic_table graphicRef52012 \" href=\"UTD.htm?3/0/3083\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/2,4-9\">",
"     2,4-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Posttraumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children younger than 10 years of age who sustain a fracture of the proximal tibia are at risk for developing valgus deformity secondary to selective medial physeal overgrowth in response to the fracture or the healing response (Cozen fracture) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posttraumatic valgus deformity may occur even in minimally displaced fractures that maintain good alignment and heal successfully (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79339 \" href=\"UTD.htm?30/11/30900\">",
"     image 1",
"    </a>",
"    ). Thus, all proximal tibial fractures in children younger than 10 years should be followed over time to ensure maintenance of alignment. Deformity usually develops within one year of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=see_link\">",
"     \"Proximal tibial fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knock-knees also may be caused by many",
"    <span class=\"nowrap\">",
"     systemic/metabolic",
"    </span>",
"    medical problems (eg, rickets, mucopolysaccharidosis), skeletal dysplasia (eg, multiple epiphyseal dysplasia, pseudoachondroplasia), and neoplasms (eg, multiple hereditary exostoses) (",
"    <a class=\"graphic graphic_table graphicRef71973 \" href=\"UTD.htm?14/46/15085\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/4,13,14\">",
"     4,13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link\">",
"     \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35082?source=see_link&amp;anchor=H17#H17\">",
"     \"Complications and management of the mucopolysaccharidoses\", section on 'Genu valgum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant valgus deformity (ie, intermalleolar distance &gt;8 cm with patellas facing straight ahead and the femoral condyles touching) and short stature are clues to these pathologic causes of knock-knees. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presenting complaints for children with knock-knees may include concerns about the appearance of the legs, clumsiness, falling, flat feet, and medial foot or knee pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is the most important component of the evaluation of the child with knock-knees. Radiographs are necessary in a minority of cases. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Radiographs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history in a child with knock-knees include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/4-7,9\">",
"     4-7,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Growth and development",
"     </li>",
"     <li>",
"      Onset (ie, before or after birth? Before or after walking?)",
"     </li>",
"     <li>",
"      Progression (physiologic valgus typically progresses between ages two and four years and improves between age four and seven years; pathologic valgus worsens after age four years)",
"     </li>",
"     <li>",
"      Associated complaints (pain, limp, tripping, falling)",
"     </li>",
"     <li>",
"      Previous treatment (if any) and treatment response",
"     </li>",
"     <li>",
"      History of infection, trauma, or fracture (that may have caused asymmetric growth retardation or stimulation)",
"     </li>",
"     <li>",
"      History of joint",
"      <span class=\"nowrap\">",
"       swelling/warmth",
"      </span>",
"      (suggestive of rheumatoid arthritis)",
"     </li>",
"     <li>",
"      Family history (short stature, skeletal dysplasia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to ascertain the parents' perceptions of the deformity and concerns regarding gait, appearance, and function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the physical examination of the child with knock-knees include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/4-6,9\">",
"     4-6,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Length/height",
"      </span>",
"      &ndash; The child's length or height should be plotted on the standardized growth curve ((",
"      <a class=\"graphic graphic_figure graphicRef67950 graphicRef63399 \" href=\"UTD.htm?1/17/1304\">",
"       figure 4A-B",
"      </a>",
"      ) [for boys] and (",
"      <a class=\"graphic graphic_figure graphicRef80511 graphicRef77249 \" href=\"UTD.htm?38/61/39895\">",
"       figure 5A-B",
"      </a>",
"      ) [for girls]).",
"      <span class=\"nowrap\">",
"       Length/height",
"      </span>",
"      less than the 3rd percentile in a child with knock-knees is a potential clue to a pathologic condition (eg, renal osteodystrophy, skeletal dysplasia) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/15\">",
"       15",
"      </a>",
"      ]. Less severe short stature (eg, 10th or 25th percentile) may be cause for concern if the child has other manifestations of a pathologic condition associated with knock-knees (",
"      <a class=\"graphic graphic_table graphicRef71973 \" href=\"UTD.htm?14/46/15085\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Weight &ndash; The child's weight should be measured and body mass index calculated ((",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) [for boys] and (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) [for girls]). Obese children may develop idiopathic genu valgum [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"       \"Clinical evaluation of the obese child and adolescent\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Focused examination of the lower extremities &ndash; Focused examination of the lower extremities in young children may be easier if performed with the child sitting on the parent's lap. With the child in the seated position, the knees should be extended and the legs rotated so that the patellas are pointed straight ahead. This maneuver is necessary to accurately estimate lower-extremity angular alignment because it removes any apparent varus or valgus that may be caused by tibial torsion or femoral anteversion. Flat feet and external tibial torsion may accompany knock-knees and accentuate its appearance [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      With the knees extended, the patellas pointed straight ahead, and the femoral condyles touching, a gross estimate of the amount of valgus can be measured. Greater than 8 cm between the medial malleoli is considered abnormal at any age [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/16\">",
"       16",
"      </a>",
"      ]. This measurement provides a reproducible, objective, nonradiographic method of monitoring progression or improvement of the deformity over multiple clinic visits.",
"      <br/>",
"      <br/>",
"      Additional components of the lower-extremity examination include [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/4,6\">",
"       4,6",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assessment of symmetry, including leg-length discrepancy (asymmetry or unilateral involvement is suggestive of pathologic genu valgum)",
"     </li>",
"     <li>",
"      Assessment of leg length (shortening of the legs may suggest skeletal dysplasia) (",
"      <a class=\"graphic graphic_table graphicRef71973 \" href=\"UTD.htm?14/46/15085\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Determination of the site of angulation: proximal tibia (Cozen fracture), knee (ligamentous hyperlaxity, arthritis), or distal",
"      <span class=\"nowrap\">",
"       femur/distal",
"      </span>",
"      femur and tibia (metabolic bone disease, skeletal dysplasia)",
"     </li>",
"     <li>",
"      Assessment of the iliotibial band for tightness with the Ober test (",
"      <a class=\"graphic graphic_figure graphicRef63810 \" href=\"UTD.htm?14/41/14992\">",
"       figure 6",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpation of the epiphysis and metaphysis for exostoses (a clue to hereditary multiple exostoses) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Observation of gait &ndash; If the child is ambulatory, the child's gait should be observed as the child walks toward and away from the examiner [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/2\">",
"       2",
"      </a>",
"      ]. The foot progression and patellar progression angles should be noted. These angles describe the alignment of the foot and patella, respectively, as they relate to the direction that the patient is moving. For example, an internal foot progression angle describes a foot that points toward the midline as the patient walks forward. An external patellar progression angle describes a patella that points laterally as the patient walks forward.",
"      <br/>",
"      <br/>",
"      The presence or absence of a medial thrust during ambulation also should be noted [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/4\">",
"       4",
"      </a>",
"      ]. A medial thrust is a brief medial knee-joint protrusion during the stance phase of gait that suggests incompetence of the knee ligaments. A medial thrust may be characteristic of pathologic genu valgum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fit within the age-appropriate progression of valgus rarely need radiographs (",
"    <a class=\"graphic graphic_figure graphicRef74063 \" href=\"UTD.htm?37/33/38417\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53765 \" href=\"UTD.htm?38/10/39085\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Normal physiologic alignment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications &ndash; We suggest that radiographs be obtained in children with clinical features suggestive of pathologic valgus (",
"      <a class=\"graphic graphic_table graphicRef52012 \" href=\"UTD.htm?3/0/3083\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/2,4-9\">",
"       2,4-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Technique &ndash; Proper radiographic technique is essential to obtaining useful images. If possible, teleograms (the entire lower extremity from the hips to the feet of both lower extremities) should be obtained with the patient standing (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60274 \" href=\"UTD.htm?36/60/37828\">",
"       image 2",
"      </a>",
"      ). Whether or not the child is standing, it is paramount that the patellas (not the feet) are pointing straight ahead. Otherwise, the amount of valgus cannot be accurately assessed. Proper positioning permits serial comparison if necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Findings &ndash; The radiographs are reviewed to [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/5,6,9\">",
"       5,6,9",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Determine which bones are affected (eg, femur, tibia, or both)",
"     </li>",
"     <li>",
"      Determine which aspects of the bone are involved: bony diaphysis (trauma), metaphysis (skeletal dysplasia), physis (rickets, skeletal dysplasia), epiphysis (skeletal dysplasia)",
"     </li>",
"     <li>",
"      Determine the tibiofemoral angle (the angle between the long axis of the tibia and the long axis of the femur)",
"     </li>",
"     <li>",
"      Assess the width of the physis (growth plate) and height of the epiphysis",
"     </li>",
"     <li>",
"      Look for characteristic features of skeletal dysplasias (eg, flattening of the distal femoral and proximal epiphysis in multiple epiphyseal dysplasia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional evaluation may be necessary if radiographs are suggestive of metabolic bone disease or skeletal dysplasia (",
"    <a class=\"graphic graphic_table graphicRef71973 \" href=\"UTD.htm?14/46/15085\">",
"     table 1",
"    </a>",
"    ). The evaluation varies depending upon the suspected condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link\">",
"     \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"     \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children with clinical features suggestive of pathologic valgus (",
"    <a class=\"graphic graphic_table graphicRef52012 \" href=\"UTD.htm?3/0/3083\">",
"     table 2",
"    </a>",
"    ) be referred to an orthopedic surgeon",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other specialist as indicated by the suspected underlying condition (eg, nephrologist, endocrinologist, geneticist, rheumatologist) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Physiologic knock-knees",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of physiologic valgus is spontaneous improvement between four and seven years of age (",
"    <a class=\"graphic graphic_figure graphicRef74063 \" href=\"UTD.htm?37/33/38417\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53765 \" href=\"UTD.htm?38/10/39085\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/1\">",
"     1",
"    </a>",
"    ]. Excessive asymmetric genu valgum also may resolve spontaneously if there are no physeal or bony abnormalities on radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that children younger than 10 years of age with physiologic valgus (as defined above (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Physiologic valgus'",
"    </a>",
"    above)) be managed with observation and parental reassurance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/4,7,9\">",
"     4,7,9",
"    </a>",
"    ]. Patients can be followed at four- to six-month intervals to ensure resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Bracing is ineffective, unnecessary, poorly tolerated, and may have negative psychosocial sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/5,18,19\">",
"     5,18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Physiologic valgus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surgical treatment may be indicated for children older than 10 years with symptoms (eg, difficulty running, knee or foot pain) or those with significant deformity (&gt;8 cm between the medial malleoli when the patellas are facing forward and the femoral condyles touching) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/20\">",
"     20",
"    </a>",
"    ]. Surgical treatment is usually deferred until the child is at least 10 years old to allow adequate time for spontaneous correction.",
"   </p>",
"   <p>",
"    Surgical procedures for correction of genu valgum include guided growth through hemiepiphysiodesis (arrest of the growth plate on the apical side of the deformity) and tibial or femoral osteotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pathologic knock-knees",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pathologic knock-knees depends upon the underlying problem.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posttraumatic &ndash; Posttraumatic valgus deformity is more likely to resolve spontaneously in children younger than five years than in older children [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/21\">",
"       21",
"      </a>",
"      ]. Children younger than five years can be managed with observation. Older children, and children whose deformities do not fully correct spontaneously, may benefit from surgical correction with hemiepiphysiodesis (arrest of the growth plate on the apical side of the deformity) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic conditions &ndash; Once a diagnosis is made, medical therapy for the primary disease should be optimized (if effective medical therapy is available) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/9\">",
"       9",
"      </a>",
"      ]. Medical management may result in some improvement in lower-extremity alignment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical therapy should be reserved for patients with residual therapy after medical optimization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/8\">",
"     8",
"    </a>",
"    ]. Surgical therapy for pathologic knock-knees may include guided growth through hemiepiphysiodesis (arrest of the growth plate on the apical side of the deformity) or tibial or femoral osteotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of physiologic valgus is spontaneous improvement between four and seven years of age (",
"    <a class=\"graphic graphic_figure graphicRef74063 \" href=\"UTD.htm?37/33/38417\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53765 \" href=\"UTD.htm?38/10/39085\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pathologic genu valgum can affect knee function, leading to abnormal tracking of the patella, increased load on the lateral compartment of the knee, and stress on the medial collateral ligament [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/23\">",
"     23",
"    </a>",
"    ]. Long-term sequelae may include meniscal tears (medial, lateral, or both), patellofemoral pain or subluxation, and increased risk of osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower-extremity alignment goes through a predictable progression from varus (bow-legs) to valgus (knock-knees) over the first seven years of life (",
"      <a class=\"graphic graphic_figure graphicRef74063 \" href=\"UTD.htm?37/33/38417\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53765 \" href=\"UTD.htm?38/10/39085\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal physiologic alignment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most young children with knock-knees have physiologic valgus. Physiologic valgus is defined by a tibiofemoral angle within two standard deviations of the mean for age. Characteristic features of physiologic valgus include age between two and five years, symmetric valgus, normal stature, and lack of symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physiologic valgus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathologic causes of knock-knees in children include posttraumatic (eg, Cozen fracture), rickets, skeletal dysplasia, mucopolysaccharidosis, and neoplasms (",
"      <a class=\"graphic graphic_table graphicRef71973 \" href=\"UTD.htm?14/46/15085\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6199/abstract/3\">",
"       3",
"      </a>",
"      ]. Clinical features suggestive of pathologic valgus are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef52012 \" href=\"UTD.htm?3/0/3083\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathologic valgus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that radiographs be obtained in children with clinical features suggestive of pathologic valgus (",
"      <a class=\"graphic graphic_table graphicRef52012 \" href=\"UTD.htm?3/0/3083\">",
"       table 2",
"      </a>",
"      ). Radiographs should include both legs from the hips to the feet, with the child standing and the patellas pointing straight ahead (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60274 \" href=\"UTD.htm?36/60/37828\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with clinical features suggestive of pathologic valgus (",
"      <a class=\"graphic graphic_table graphicRef52012 \" href=\"UTD.htm?3/0/3083\">",
"       table 2",
"      </a>",
"      ) be referred to an orthopedic surgeon",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other specialist as indicated by the suspected underlying condition (eg, nephrologist, endocrinologist, geneticist, rheumatologist). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of physiologic knock-knees is spontaneous improvement between age four and seven years. We recommend that children younger than 10 years with physiologic valgus (as defined in the text (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Physiologic valgus'",
"      </a>",
"      above)) be managed with observation and parental reassurance (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Orthotics (braces, splints, shoe inserts) are ineffective and unnecessary, and may have negative psychosocial sequelae. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Physiologic knock-knees'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of pathologic valgus depends upon the underlying problem. Medical therapy for the primary disease should be optimized (if effective medical therapy is available). Surgical therapy should be reserved for patients with residual deformity after medical optimization. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathologic valgus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/1\">",
"      Salenius P, Vankka E. The development of the tibiofemoral angle in children. J Bone Joint Surg Am 1975; 57:259.",
"     </a>",
"    </li>",
"    <li>",
"     Shoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1158.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/3\">",
"      White GR, Mencio GA. Genu Valgum in Children: Diagnostic and Therapeutic Alternatives. J Am Acad Orthop Surg 1995; 3:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/4\">",
"      Kling TF Jr. Angular deformities of the lower limbs in children. Orthop Clin North Am 1987; 18:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/5\">",
"      Greene WB. Genu varum and genu valgum in children: differential diagnosis and guidelines for evaluation. Compr Ther 1996; 22:22.",
"     </a>",
"    </li>",
"    <li>",
"     The knee and leg. In: Clinical Pediatric Orthopedics The Art of Diagnosis and Principles of Management, Tachdjian MO (Ed), Appleton &amp; Lange, Stamford, CT 1997. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/7\">",
"      Sass P, Hassan G. Lower extremity abnormalities in children. Am Fam Physician 2003; 68:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/8\">",
"      Scherl SA. Common lower extremity problems in children. Pediatr Rev 2004; 25:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/9\">",
"      Bruce RW Jr. Torsional and angular deformities. Pediatr Clin North Am 1996; 43:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/10\">",
"      Ogden JA, Ogden DA, Pugh L, et al. Tibia valga after proximal metaphyseal fractures in childhood: a normal biologic response. J Pediatr Orthop 1995; 15:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/11\">",
"      Cozen L. Knock-knee deformity in children. Congenital and acquired. Clin Orthop Relat Res 1990; :191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/12\">",
"      Jackson DW, Cozen L. Genu valgum as a complication of proximal tibial metaphyseal fractures in children. J Bone Joint Surg Am 1971; 53:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/13\">",
"      Barrett IR, Papadimitriou DG. Skeletal disorders in children with renal failure. J Pediatr Orthop 1996; 16:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/14\">",
"      Odunusi E, Peters C, Krivit W, Ogilvie J. Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention. J Pediatr Orthop 1999; 19:270.",
"     </a>",
"    </li>",
"    <li>",
"     Herring JA. Skeletal Dysplasias. In: Tachjidan's Pediatric Orthopaedics, 4th ed, Saunders, Philadelphia 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/16\">",
"      Heath CH, Staheli LT. Normal limits of knee angle in white children--genu varum and genu valgum. J Pediatr Orthop 1993; 13:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/17\">",
"      Stieber JR, Dormans JP. Manifestations of hereditary multiple exostoses. J Am Acad Orthop Surg 2005; 13:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/18\">",
"      Greene WB. Genu varum and genu valgum in children. Instr Course Lect 1994; 43:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/19\">",
"      Driano AN, Staheli L, Staheli LT. Psychosocial development and corrective shoewear use in childhood. J Pediatr Orthop 1998; 18:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/20\">",
"      Stevens PM, Maguire M, Dales MD, Robins AJ. Physeal stapling for idiopathic genu valgum. J Pediatr Orthop 1999; 19:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/21\">",
"      Tuten HR, Keeler KA, Gabos PG, et al. Posttraumatic tibia valga in children. A long-term follow-up note. J Bone Joint Surg Am 1999; 81:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/22\">",
"      Stevens PM, Pease F. Hemiepiphysiodesis for posttraumatic tibial valgus. J Pediatr Orthop 2006; 26:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6199/abstract/23\">",
"      Goldman V, Green DW. Advances in growth plate modulation for lower extremity malalignment (knock knees and bow legs). Curr Opin Pediatr 2010; 22:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6290 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-74FB0B1AEA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6199=[""].join("\n");
var outline_f6_3_6199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL PHYSIOLOGIC ALIGNMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES OF KNOCK-KNEES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physiologic valgus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathologic valgus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Posttraumatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Physiologic knock-knees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pathologic knock-knees",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6290\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6290|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/11/30900\" title=\"diagnostic image 1\">",
"      Cozen fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/60/37828\" title=\"diagnostic image 2\">",
"      Standing teleogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6290|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/25/43408\" title=\"figure 1\">",
"      Genu varum and valgum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/33/38417\" title=\"figure 2\">",
"      Lower extremity alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/10/39085\" title=\"figure 3\">",
"      Tibio-femoral progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/44/31426\" title=\"figure 4A\">",
"      WHO length for age boys 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/1/44050\" title=\"figure 4B\">",
"      CDC stature for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/51/30514\" title=\"figure 5A\">",
"      WHO length for age girls 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/10/29858\" title=\"figure 5B\">",
"      CDC stature for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/41/14992\" title=\"figure 6\">",
"      Ober test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6290|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/46/15085\" title=\"table 1\">",
"      Knock-knees DDx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/0/3083\" title=\"table 2\">",
"      Knock-knees red flags",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27511?source=related_link\">",
"      Approach to the child with bow-legs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=related_link\">",
"      Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35082?source=related_link\">",
"      Complications and management of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=related_link\">",
"      Proximal tibial fractures in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6200="Azithromycin (systemic): Pediatric drug information";
var content_f6_3_6200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azithromycin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=see_link\">",
"    see \"Azithromycin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=see_link\">",
"    see \"Azithromycin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14310218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Warning for Azithromycin Heart Risks",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) has issued a safety warning that azithromycin (Zithromax&reg; or Zmax&reg;) may cause prolonged cardiac repolarization and QT interval, increasing the risk of cardiac arrhythmia and torsade de pointes. Patients at particular risk include those with known risk factors such as existing QT-interval prolongation, a history of torsade de pointes, congenital long QT syndrome, uncompensated heart failure, use of drugs known to prolong the QT interval, uncorrected hypokalemia or hypomagnesemia, or clinically significant bradycardia.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The warning results from FDA review of a research study and a subsequent study conducted by a manufacturer, both assessing the potential for azithromycin to cause abnormal cardiac activity.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare providers should be aware of the potential for QT-interval prolongation and heart arrhythmias when prescribing or administering azithromycin for patients who are already at risk for cardiovascular events.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm341822.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm341822.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm304372.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm304372.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7983183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zithromax&reg;;",
"     </li>",
"     <li>",
"      Zithromax&reg; TRI-PAK&trade;;",
"     </li>",
"     <li>",
"      Zithromax&reg; Z-PAK&reg;;",
"     </li>",
"     <li>",
"      Zmax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7983184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Azithromycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Azithromycin;",
"     </li>",
"     <li>",
"      Azithromycin for Injection;",
"     </li>",
"     <li>",
"      CO Azithromycin;",
"     </li>",
"     <li>",
"      Dom-Azithromycin;",
"     </li>",
"     <li>",
"      GD-Azithromycin;",
"     </li>",
"     <li>",
"      Mylan-Azithromycin;",
"     </li>",
"     <li>",
"      Novo-Azithromycin;",
"     </li>",
"     <li>",
"      PHL-Azithromycin;",
"     </li>",
"     <li>",
"      PMS-Azithromycin;",
"     </li>",
"     <li>",
"      PRO-Azithromycin;",
"     </li>",
"     <li>",
"      ratio-Azithromycin;",
"     </li>",
"     <li>",
"      Riva-Azithromycin;",
"     </li>",
"     <li>",
"      Sandoz-Azithromycin;",
"     </li>",
"     <li>",
"      Zithromax&reg;;",
"     </li>",
"     <li>",
"      Zithromax&reg; For Intravenous Injection;",
"     </li>",
"     <li>",
"      Zmax SR&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10585820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Macrolide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12824328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bronchopulmonary dysplasia, prevention: Oral, I.V.: 10 mg/kg/dose once daily for 7 days, followed by 5 mg/kg/dose once daily  for 5 weeks was used in 19 mechanically ventilated premature neonates (mean GA: 25.6 weeks; PNA: &lt;72 hours; birth weight &le;1000 g) and decreased corticosteroid use and duration of mechanical ventilation compared to placebo (Ballard, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pertussis, treatment and postexposure prophylaxis: Oral: 10 mg/kg/dose once daily for 5 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10585964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=see_link\">",
"      see \"Azithromycin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Extended release suspension (Zmax&reg;) is not interchangeable with immediate-release formulations. All doses are expressed as immediate release azithromycin unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 1-5 months: Pertussis: 10 mg/kg/dose once daily for 5 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;6 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Respiratory tract infections: 10 mg/kg on day 1 (maximum dose: 500 mg) followed by 5 mg/kg/day (maximum dose: 250 mg) once daily on days 2-5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Community-acquired pneumonia: 10 mg/kg (maximum dose: 500 mg) once daily for 3 days or 10 mg/kg (maximum dose: 500 mg) as a single dose on the first day followed by 5 mg/kg/day (maximum dose: 250 mg) on days 2 through 5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative regimen for community-acquired pneumonia: Extended release suspension: 60 mg/kg as a single dose (maximum dose: 2 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Otitis media:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Single dose regimen: 30 mg/kg as a single dose (maximum dose: 1500 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Three-day regimen: 10 mg/kg (maximum dose: 500 mg/day) once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Five-day regimen: 10 mg/kg on day 1 (maximum dose: 500 mg), followed by 5 mg/kg (maximum dose: 250 mg/day) once daily on days 2-5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pertussis: 10 mg/kg on day 1 (maximum dose: 500 mg), followed by 5 mg/kg/day (maximum dose: 250 mg) once daily on days 2-5 (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute bacterial sinusitis: 10 mg/kg (maximum dose: 500 mg/day) once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years: Pharyngitis, tonsillitis: 12 mg/kg/day (maximum dose: 500 mg/day) once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Babesiosis: 12 mg/kg/day (maximum dose: 600 mg) once daily for 7-10 days with oral atovaquone 40 mg/kg/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chancroid: Single 20 mg/kg dose (maximum dose: 1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlamydial urethritis, uncomplicated or cervicitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &lt;8 years and &lt;45 kg: 20 mg/kg as a single dose (maximum dose: 1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;8 years and &ge;45 kg: Single 1 g dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endocarditis prophylaxis: 15 mg/kg/dose (maximum dose: 500 mg) 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     MAC, disseminated (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Treatment: 10-12 mg/kg/day (maximum dose: 500 mg/day) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Primary prevention: Preferred: 20 mg/kg once weekly (maximum dose: 1200 mg/dose) or alternatively, 5 mg/kg/day once daily (maximum dose: 250 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Secondary prevention: 5 mg/kg/day once daily (maximum dose: 250 mg/day) in combination with ethambutol, with or without rifabutin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;6 years, weight &ge;25 kg and Adolescents:",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     , chronic infection in CF patient:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;25 kg to &lt;40 kg: 250 mg on Mondays, Wednesdays, Fridays (MWF). If intolerable side effects occur, decrease dose to twice a week, or if necessary, once weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;40 kg: 500 mg on Mondays, Wednesdays, Fridays (MWF). If intolerable side effects occur, decrease dose to twice a week, or if necessary, once weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bacterial sinusitis: 500 mg once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative regimen for bacterial sinusitis: Extended release suspension: Single 2 g dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Community-acquired pneumonia, pharyngitis/tonsillitis, bacterial exacerbation of COPD, skin and soft tissue infections: 500 mg on day 1 followed by 250 mg/day once daily on days 2-5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative regimen for bacterial exacerbation of COPD: 500 mg once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative regimen for community-acquired pneumonia: Extended release suspension: Single 2 g dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chancroid or nongonococcal urethritis and cervicitis due to",
"     <i>",
"      C. trachomatis",
"     </i>",
"     : Single 1 g dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Urethritis and cervicitis due to",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     : Single 2 g dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endocarditis prophylaxis: 500 mg dose 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention of disseminated MAC: 1200 mg once weekly alone or in combination with rifabutin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment and secondary prevention of disseminated MAC: 500 mg once daily in combination with ethambutol, with or without rifabutin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pertussis: 500 mg on day 1 followed by 250 mg once daily on days 2-5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Not currently FDA approved; limited published data in children. A pharmacokinetic study of children 6 months to 16 years used 10 mg/kg (maximum dose: 500 mg); however, this was a single-dose pharmacokinetic study meant to guide dosing for larger trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &ge;16 years and Adults: 500 mg once daily for 2 days followed by a switch to",
"     <b>",
"      oral",
"     </b>",
"     azithromycin therapy (500 mg once daily to complete a 7- to 10-day course of therapy).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7983340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as dihydrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 500 mg [DSC] [contains sodium 114 mg (4.96 mEq)/vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as monohydrate [strength expressed as base]: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Microspheres for suspension, extended release, oral, as dihydrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zmax&reg;: 2 g/bottle (60 mL) [contains sodium 148 mg/bottle, sucrose 19 g/bottle; cherry-banana flavor; product contains azithromycin 27 mg/mL after constitution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as dihydrate [strength expressed as base]: 100 mg/5 mL (15 mL); 200 mg/5 mL (15 mL, 22.5 mL, 30 mL); 1 g/packet (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 100 mg/5 mL (15 mL) [contains sodium 3.7 mg/5 mL; cherry-cr&egrave;me de vanilla-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 200 mg/5 mL (15 mL, 22.5 mL, 30 mL) [contains sodium 7.4 mg/5 mL; cherry-cr&egrave;me de vanilla-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 1 g/packet (3s, 10s) [contains sodium 37 mg/packet; banana-cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as monohydrate [strength expressed as base]: 100 mg/5 mL (15 mL); 200 mg/5 mL (15 mL, 22.5 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as anhydrous: 250 mg, 500 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dihydrate [strength expressed as base]: 250 mg, 500 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 250 mg [contains sodium 0.9 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 500 mg [contains sodium 1.8 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg;: 600 mg [contains sodium 2.1 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg; TRI-PAK&trade;: 500 mg [contains sodium 1.8 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zithromax&reg; Z-PAK&reg;: 250 mg [contains sodium 0.9 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as monohydrate [strength expressed as base]: 250 mg, 500 mg, 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7983186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release microspheres",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10585984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Shake suspension well before use; immediate release oral suspension, tablet, or the 1 g suspension regimen formulation may be administered with or without food; do not administer with antacids that contain aluminum or magnesium; azithromycin 1 g oral suspension for a single-dose regimen should be prepared by mixing contents of 1 packet with approximately 60 mL of water. Have the patient drink the entire contents immediately; add an additional 60 mL of water, mix, and drink.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release oral suspension: Prepare 2 g azithromycin suspension by reconstituting with 60 mL of water (final concentration: 27 mg/mL). Shake suspension well before use; administer on an empty stomach 1 hour before or 2 hours after a meal. May be administered without regard to antacids containing aluminum or magnesium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"     <b>",
"      Do not give I.M. or by direct I.V. injection.",
"     </b>",
"     Administer I.V. infusion at a final concentration of 1 mg/mL over 3 hours; for a 2 mg/mL concentration, infuse over 1 hour; do not infuse over a period of less than 60 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F7983259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS (with or without 20 mEq/L KCl), Normosol&reg;-M in D",
"     <sub>",
"      5",
"     </sub>",
"     , Normosol&reg;-R in D",
"     <sub>",
"      5",
"     </sub>",
"     , LR, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Bivalirudin, caspofungin, dexmedetomidine, diphenhydramine, dolasetron, doripenem, droperidol, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), ondansetron, tigecycline.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amikacin, aztreonam, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, ciprofloxacin, clindamycin, famotidine, fentanyl, furosemide, gentamicin, imipenem/cilastatin, ketorolac, levofloxacin, morphine, piperacillin/tazobactam, potassium chloride, ticarcillin/clavulanate potassium, tobramycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10585827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials of injection, dry powder for oral suspension, and tablets at room temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release: After reconstitution, multiple dose oral suspension may be stored for 10 days at room temperature or in the refrigerator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release microspheres: After reconstitution, store at room temperature; do not refrigerate or freeze; must be consumed within 12 hours following reconstitution. Any suspension remaining after dosing must be discarded.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: After reconstituting 500 mg vial at a concentration of 100 mg/mL, solution is stable for 24 hours at room temperature. If solution is further diluted with a compatible diluent to a 1-2 mg/mL concentration, this solution is stable for 24 hours at room temperature or 7 days if refrigerated.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10585821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of acute otitis media due to",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     , or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (FDA approved in pediatric patient ages &gt;6 months); treatment of pharyngitis/tonsillitis due to",
"     <i>",
"      S. pyogenes",
"     </i>",
"     (FDA approved in ages &ge;2 years and adults); treatment of community-acquired pneumonia due to susceptible organisms, including",
"     <i>",
"      C. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      M. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (FDA approved in ages &ge;6 months and adults). [Oral azithromycin is not indicated for use in patients with pneumonia who have moderate to severe disease and judged to be inappropriate for oral therapy or have any risk factors such as cystic fibrosis, nosocomial infection, known or suspected bacteremia, hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia)]; treatment of sinusitis or COPD exacerbation due to",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     , or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (FDA approved in adults); treatment of infections of the skin and skin structure, acute pelvic inflammatory disease, chancroid, and urethritis and cervicitis due to susceptible strains of",
"     <i>",
"      C. trachomatis",
"     </i>",
"     ,",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      Mycoplasma pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      M. avium",
"     </i>",
"     complex,",
"     <i>",
"      C. psittaci",
"     </i>",
"     , and",
"     <i>",
"      C. pneumoniae",
"     </i>",
"     (FDA approved in adults). Has also been used for treatment of babesiosis, pertussis, endocarditis prophylaxis in penicillin allergic patients, and cystic fibrosis lung disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of community-acquired pneumonia due to susceptible",
"     <i>",
"      C. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      L. pneumophilia",
"     </i>",
"     ,",
"     <i>",
"      M. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ; treatment of pelvic inflammatory disease due to susceptible",
"     <i>",
"      C. pneumonia",
"     </i>",
"     ,",
"     <i>",
"      N. gonorrhoeaee",
"     </i>",
"     , or",
"     <i>",
"      M. hominis",
"     </i>",
"     (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7983163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Azithromycin may be confused with azathioprine, erythromycin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zithromax&reg; may be confused with Fosamax&reg;, Zinacef&reg;, Zovirax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7983246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, cramping, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: (with I.V. administration): Injection site pain, inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, aggressive behavior agitation, allergic reaction, anaphylaxis, anemia, angioedema, anxiety, arrhythmia (including ventricular tachycardia), arthralgia, bronchospasm, candidiasis, chest pain, cholestatic jaundice, conjunctivitis (pediatric patients), constipation, cough increased, deafness, dehydration, dermatitis (fungal), diaphoresis, dizziness, dyspepsia, eczema, edema, enteritis, erythema multiforme (rare), facial edema, fatigue fever, flatulence, fungal infection, gastritis, headache, hearing disturbance, hearing loss, hepatic failure, hepatic necrosis, hepatitis, hyperactivity, hyperkinesia, hypotension, insomnia, interstitial nephritis, jaundice, leukopenia, LFTs increased, loss of smell, loss of taste, malaise, melena, mucositis, nephritis, nervousness, neutropenia (mild), oral candidiasis, oral moniliasis, pain, palpitation, pancreatitis, paresthesia, pharyngitis, photosensitivity, pleural effusion, pseudomembranous colitis, pyloric stenosis, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (rare), rhinitis, seizure, smell perversion, somnolence, somnolence, Stevens-Johnson syndrome (rare), syncope, taste perversion, thrombocytopenia, tinnitus, tongue discoloration (rare), torsade de pointes (rare), toxic epidermal necrolysis (rare), urticaria, vertigo, vesiculobullous rash, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10585822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azithromycin or any component, erythromycin, other macrolide, or ketolide antibiotics; concurrent use of pimozide due to potential cardiotoxicity; history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10585824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired hepatic function and patients with severe renal impairment (GFR &lt;10 mL/minute). Use with caution in patients at risk for prolonged cardiac repolarization; macrolides have been associated with rare QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and ventricular arrhythmias, including torsade de pointes. Use with caution in patients with myasthenia gravis; exacerbation and new onset of symptoms have occurred.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10585823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral azithromycin should not be used to treat pneumonia that is considered inappropriate for outpatient oral therapy. May mask or delay symptoms of incubating gonorrhea or syphilis so appropriate culture and susceptibility tests should be performed prior to initiating azithromycin. Pseudomembranous colitis, including",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD) ranging from mild diarrhea to fatal colitis has been reported with use of antibiotics, including azithromycin; CDAD has been observed &gt;2 months postantibiotic treatment. If CDAD is suspected or confirmed, azithromycin may need to be discontinued and CDAD treatment and supportive care initiated. Serious allergic reactions, including anaphylaxis, angioedema, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported; reappearance of allergic reaction may occur shortly after discontinuation of symptomatic treatment even without further azithromycin exposure. Patients who experience allergic reactions may require prolonged periods of observation and symptomatic treatment, possibly due to the drug's long tissue half-life.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hepatic impairment, including hepatocellular and/or cholestatic hepatitis, with or without jaundice, hepatic necrosis, failure, and death have been reported in older children and adults; it may be accompanied by malaise, nausea, vomiting, abdominal colic, and fever; discontinue use immediately if signs/symptoms of hepatic impairment occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7983249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7983250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Azithromycin (Systemic) may enhance the QTc-prolonging effect of Amiodarone.  Management: The concomitant use of amiodarone, which has a high risk for QTc prolongation, with azithromycin, which may also prolong the QT interval, should be avoided.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivermectin (Systemic): Azithromycin (Systemic) may increase the serum concentration of Ivermectin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May increase the serum concentration of Azithromycin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Azithromycin (Systemic) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10585826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Presence of food does not affect bioavailability of the tablet formulation, immediate release oral suspension, or the 1 g suspension regimen. Azithromycin extended release suspension has increased absorption (23%) when given with a high-fat meal.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7983214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7983215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Azithromycin crosses the placenta. Fetal malformations have not been observed following maternal use of azithromycin. The maternal serum half-life of azithromycin is unchanged in early pregnancy and decreased at term; however, high concentrations of azithromycin are sustained in the myometrium and adipose tissue. Azithromycin is recommended for the treatment of several infections, including chlamydia, gonococcal infections, and",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC) in pregnant patients (consult current guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10585985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, WBC with differential; number and type of stools/day for diarrhea; monitor patients receiving azithromycin and drugs known to interact with erythromycin (ie, theophylline, digoxin, anticoagulants, triazolam) since there are still very few studies examining drug-drug interactions with azithromycin",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10585864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial RNA-dependent protein synthesis by binding to the 50S ribosomal subunit which results in the blockage of transpeptidation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10585865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive tissue distribution into skin, lungs, tonsils, bone, prostate, cervix; CSF concentrations are low; crosses the placenta; excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 31.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 7% to 51% (concentration-dependent and dependent on alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet, immediate release oral suspension: 34% to 52%; extended release oral suspension: 28% to 43%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4 months to 15 years: 54.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 68 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release oral suspension: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 50% of dose is excreted unchanged in bile; 6% of dose is excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10585986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=see_link\">",
"      see \"Azithromycin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any symptoms of chest pain, heart palpitations, and yellowing of skin or eyes. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if diarrhea, abnormal heart rhythm, or allergic or photosensitivity reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, \"Diagnosis and Management of Acute Otitis Media,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      ,  2004, 113(5):1451-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/15121972/pubmed\" id=\"15121972\" target=\"_blank\">",
"        15121972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ballard HO, Anstead MI, and Shook LA, \"Azithromycin in the Extremely Low Birth Weight Infant for the Prevention of Bronchopulmonary Dysplasia: A Pilot Study,\"",
"      <i>",
"       Respir Res",
"      </i>",
"      , 2007, 8:41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/17550598/pubmed\" id=\"17550598\" target=\"_blank\">",
"        17550598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bryant KA, Humbaugh K, Brothers K, et al, \"Measures to Control an Outbreak of Pertussis in a Neonatal Intermediate Care Nursery After Exposure to a Healthcare Worker,\"",
"      <i>",
"       Infect Control Hosp Epidemiol",
"      </i>",
"      , 2006, 27(6):541-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/16755471/pubmed\" id=\"16755471\" target=\"_blank\">",
"        16755471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, Workowski KA, and Berman SM, \"Sexually Transmitted Diseases Treatment Guidelines, 2006,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-11):1-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/16888612/pubmed\" id=\"16888612\" target=\"_blank\">",
"        16888612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drew RH and Gallis HA, &ldquo;Azithromycin-Spectrum of Activity, Pharmacokinetics, and Clinical Applications,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1992, 12(3):161-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/1319048 /pubmed\" id=\"1319048 \" target=\"_blank\">",
"        1319048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foulds G, Shepard RM, and Johnson RB, &ldquo;The Pharmacokinetics of Azithromycin in Human Serum and Tissues,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1990, 25(Suppl A):73-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/2154441/pubmed\" id=\"2154441\" target=\"_blank\">",
"        2154441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobs RF, Maples HD, Aranda JV, et al, \"Pharmacokinetics of Intravenously Administered Azithromycin in Pediatric Patients,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2005, 24(1):34-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/15665708/pubmed\" id=\"15665708\" target=\"_blank\">",
"        15665708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lockwood AM, Cole S, and Rabinovich M, \"Azithromycin-Induced Liver Injury,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2010, 67(10):810-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/20479103/pubmed\" id=\"20479103\" target=\"_blank\">",
"        20479103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC, Koranyi KI, Gadgil SD, et al, &ldquo;Pharmacokinetics of Azithromycin After Oral Administration of Multiple Doses of Suspension,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1993, 37(2):314-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/8383944 /pubmed\" id=\"8383944 \" target=\"_blank\">",
"        8383944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saiman L, Marshall BC, Mayer-Hamblett N, et al, &ldquo;Azithromycin in Patients With Cystic Fibrosis Chronically Infected With",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      : A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 290(13):1749-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/14519709 /pubmed\" id=\"14519709 \" target=\"_blank\">",
"        14519709",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, \"Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tiwari T, Murphy TV, and Moran J, \"Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2005, 54(RR-14):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/16340941/pubmed\" id=\"16340941\" target=\"_blank\">",
"        16340941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, \"Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(15):1736-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/3/6200/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15943 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6200=[""].join("\n");
var outline_f6_3_6200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14310218\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983183\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983184\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585820\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12824328\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585964\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983340\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585984\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983259\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585827\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585821\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983163\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983246\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585822\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585824\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585823\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983249\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983250\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585826\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983214\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983215\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585985\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585864\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585865\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585986\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/11/21683?source=related_link\">",
"      Azithromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13988?source=related_link\">",
"      Azithromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/2/10275?source=related_link\">",
"      Azithromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=related_link\">",
"      Azithromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=related_link\">",
"      Azithromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6201="Crigler-Najjar syndrome";
var content_f6_3_6201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Crigler-Najjar syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6201/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6201/contributors\">",
"     Namita Roy-Chowdhury, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6201/contributors\">",
"     Jayanta Roy-Chowdhury, MD, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6201/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6201/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6201/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6201/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/3/6201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of bilirubin by the liver comprises four distinct but interrelated stages (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"UTD.htm?30/51/31536\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uptake from the circulation",
"     </li>",
"     <li>",
"      Intracellular storage",
"     </li>",
"     <li>",
"      Conjugation with glucuronic acid",
"     </li>",
"     <li>",
"      Biliary excretion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In healthy people, approximately 96 percent of serum bilirubin is unconjugated. Abnormalities in any one or more of the above steps can result in hyperbilirubinemia in which there is either an elevation in unconjugated bilirubin alone or of both unconjugated and conjugated bilirubin. Complex clinical disorders, such as hepatitis or cirrhosis, can affect multiple processes, resulting in the accumulation of both unconjugated and conjugated bilirubin. In these settings, the proportion of conjugated bilirubin in plasma increases. In contrast, the unconjugated fraction alone is increased with bilirubin overproduction (as with hemolysis) without liver disease and with inherited or acquired disorders that specifically affect bilirubin uptake or glucuronidation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common causes of unconjugated hyperbilirubinemia are bilirubin overproduction, Gilbert's syndrome, and neonatal jaundice. This topic review will discuss unconjugated hyperbilirubinemia due to the rare inherited Crigler-Najjar syndromes. The other disorders are presented separately as is an approach to the patient with jaundice. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crigler-Najjar syndrome, also referred to as congenital nonhemolytic jaundice with glucuronosyltransferase deficiency, is a rare, autosomal recessive disorder of bilirubin metabolism. It has been divided into two distinct forms (types I and II) based upon the severity of the disease (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I disease is associated with severe jaundice and neurologic impairment due to bilirubin encephalopathy that can result in permanent neurologic sequelae (kernicterus).",
"     </li>",
"     <li>",
"      Type II disease is associated with a lower serum bilirubin concentration and affected patients survive into adulthood without neurologic impairment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPE I DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crigler-Najjar syndrome type I was described by Crigler and Najjar in 1952 in six infants in three families [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/1\">",
"     1",
"    </a>",
"    ]. All six infants developed severe, permanent, unconjugated hyperbilirubinemia within the first few days of life, without any evidence of hemolysis. Five of the six infants died of kernicterus by the age of 15 months. The sixth infant was free of neurologic disease until 15 years of age, when kernicterus suddenly developed; the adolescent died six months later [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/2\">",
"     2",
"    </a>",
"    ]. The syndrome occurs in all races and has been associated with consanguinity in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Molecular defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenotype of Crigler-Najjar syndrome type I can be caused by a variety of alterations in the coding sequences of the bilirubin-uridine diphosphate glucuronosyltransferase (UGT1A1) gene which is responsible for the conjugation of bilirubin (",
"    <a class=\"graphic graphic_figure graphicRef73505 \" href=\"UTD.htm?32/44/33487\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .) These mutations lead to the production of an abnormal protein, resulting in complete loss or very low levels of hepatic bilirubin-UGT (UGT1A1) activity (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/7\">",
"     7",
"    </a>",
"    ]. This is in contrast to the defect in Gilbert's syndrome in which the defect is in the promoter region, rather than the gene itself; as a result, reduced amounts of the normal protein are produced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The UGT gene exists in numerous isoforms of which UGT1A1 (bilirubin-UGT1) is the only one that contributes significantly to bilirubin conjugation in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/9\">",
"     9",
"    </a>",
"    ]. Deletions, insertions, missense mutations, or premature stop codons within the UGT1A1 gene can be located in any of the five exons comprising the UGT1A1 mRNA (",
"    <a class=\"graphic graphic_figure graphicRef73505 \" href=\"UTD.htm?32/44/33487\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Genetic alterations located in exon 1 affect the activity of only bilirubin-UGT isoform (UGT1A1); in contrast, mutations involving exons 2 to 5 affect all isoforms expressed from the UGT1A locus.",
"   </p>",
"   <p>",
"    Because of the high frequency of the Gilbert type promoter in the general population (51 percent of the Western population have at least one Gilbert type allele), some heterozygous carriers of mutations that cause Crigler-Najjar syndrome also carry the Gilbert's promoter on their normal allele. Such combined defects can lead to severe hyperbilirubinemia, since the activity of the normal allele is reduced to about 30 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This explains the frequent finding of intermediate levels of hyperbilirubinemia in the family members of patients with Crigler-Najjar syndrome, both types I and II.",
"   </p>",
"   <p>",
"    An animal model of Crigler-Najjar syndrome, the Gunn rat, was first described in 1938 and has provided an ideal model for the study of bilirubin metabolism and of therapeutic agents for this disease. The Gunn rat develops a nonhemolytic unconjugated hyperbilirubinemia, which is inherited as an autosomal recessive trait; heterozygotes are anicteric [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/14\">",
"     14",
"    </a>",
"    ]. The disease is caused by the deletion of a single guanosine residue in the common region exon 4. The serum bilirubin is all unconjugated; as a result there is no bilirubinuria or conjugated bilirubin in bile [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/15\">",
"     15",
"    </a>",
"    ]. The liver histology is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crigler-Najjar syndrome type I should be suspected in infants who develop persistent jaundice due to indirect reacting (unconjugated) bilirubin within the first few days after birth. These children have an otherwise normal liver function test profile and may have neurologic symptoms due to kernicterus. Occasional patients have late onset kernicterus in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hallmark of Crigler-Najjar syndrome type I is pure unconjugated hyperbilirubinemia, which is usually in the range of 20 to 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    but can be as high as 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Stool color is normal, but fecal urobilinogen excretion is diminished due to the marked reduction in the conjugation of bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/1-3,18-22\">",
"     1-3,18-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .) The rate of bilirubin production, bone marrow morphology, and red cell morphology and survival are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/23\">",
"     23",
"    </a>",
"    ]. Histopathologic findings are nonspecific on light and electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although other disorders can cause unconjugated hyperbilirubinemia in newborns, they can be distinguished based upon the level of hyperbilirubinemia and its duration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemolytic disorders alone do not raise serum bilirubin concentrations beyond 6 to 8",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Physiologic jaundice (a common transient elevation in serum bilirubin in newborns that is more common in East Asians) usually resolves within the first 10 days of life. Serum bilirubin concentrations are usually less than 6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in full-term neonates, and 10 to 12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in premature neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/25\">",
"       25",
"      </a>",
"      ]. It is possible that mutations in the structural region of the UGT1A1 gene account for jaundice in some of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breast milk jaundice (unconjugated hyperbilirubinemia in breast-fed newborns) is similar to neonatal jaundice except that serum bilirubin levels are higher (up to 30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      if untreated) and persist for a longer duration. They usually peak within two weeks of birth, remain elevated for 4 to 10 days, and then decline to normal over 3 to 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"       \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Distinction from type II disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more difficult problem is the distinction between Crigler-Najjar syndromes type I and II. As a general rule, type II is associated with lower serum bilirubin concentrations although values can overlap with type I, especially when there is underlying hemolysis (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ). As a result, the differential diagnosis of Crigler-Najjar syndrome type I includes Crigler-Najjar syndrome type II, with or without coexisting hemolysis.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    can help to differentiate between these disorders. The serum bilirubin concentration can be reduced by the administration of phenobarbital (60 to 120 mg for 14 days) in most patients with type II but not type I disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another difference between patients with type I and II disease is the presence of bilirubin glucuronides in bile. Conjugated bilirubin is absent or present only in trace amounts in patients with type I who have little or no UGT1A1 activity, while a significant amount of conjugated bilirubin is detectable in the bile of patients with type II (although the proportion of monoconjugates is greatly increased) (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ). Thus, chromatographic analysis of bile collected from the duodenum through an orally placed duodenal catheter or an upper gastrointestinal endoscope can be used to differentiate the two forms of the syndrome.",
"   </p>",
"   <p>",
"    DNA extracted from peripheral blood leukocytes, buccal scrapings, or any other tissue can be used to make a genetic diagnosis in both affected patients and heterozygous carriers. Furthermore, we have found that genetic analysis of chorionic villus samples or amniotic cells permits prenatal identification of the Crigler-Najjar syndrome type I genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the introduction of phototherapy and plasmapheresis to lower the serum bilirubin concentration, almost all patients with Crigler-Najjar syndrome type I died during the first 18 months of life due to kernicterus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. Most patients treated with these methods survive past puberty without significant brain damage but subsequently succumb to kernicterus later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/18,20,31,32\">",
"     18,20,31,32",
"    </a>",
"    ]. One of the reasons for treatment failure is thickening of the skin, which renders phototherapy less effective [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/32\">",
"     32",
"    </a>",
"    ]. Liver transplantation has resulted in long-term survival and is the only curative therapy presently available [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One multicenter survey published in 1996 evaluated the treatment and outcomes in 57 patients with Crigler-Najjar syndrome type I [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/32\">",
"     32",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain damage developed in 15 (26 percent)",
"     </li>",
"     <li>",
"      Five died and 10 were alive with some degree of mental or physical handicap",
"     </li>",
"     <li>",
"      Twenty-one (37 percent) had received a liver transplant at an average age of 9.1&plusmn;6.9 years; seven of these patients had some degree of brain damage at the time of transplantation, two of whom improved neurologically",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy acts by converting a portion of bilirubin IX-alfa-ZZ into its geometric and structural isomers, which are then excreted in the bile without the prerequisite for conjugation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .) The technique involves exposure to an array of 140w fluorescent lamps for 12 hours per day with devices for shielding the eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/32,35\">",
"     32,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phototherapy is widely used for the treatment of hyperbilirubinemia in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/36\">",
"     36",
"    </a>",
"    ]. Experience in older children and adults is limited. At puberty, phototherapy becomes less effective because of thickening of the skin, increased skin pigmentation, and decreased surface area in relation to body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. A case report described a successful pregnancy in a woman who was managed with intensive phototherapy and semimonthly albumin infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/37\">",
"     37",
"    </a>",
"    ]. The newborn had a serum bilirubin level similar to the mother's, needed phototherapy during the first two days of life, and did not develop bilirubin encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis is the most efficient method for rapidly reducing the serum bilirubin concentration during a crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/20,38\">",
"     20,38",
"    </a>",
"    ]. Because bilirubin is tightly bound to albumin, removal of albumin during plasmapheresis results in equimolar clearance of bilirubin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Calcium phosphate supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in Gunn rats provided support for the hypothesis that oral amorphous calcium phosphate traps unconjugated bilirubin in the gut, lowering the serum bilirubin concentration by 20 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with Crigler-Najjar syndrome type 1 who were being treated with phototherapy also had a modest (18 percent) reduction in their serum bilirubin concentrations after oral administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    , which generates amorphous calcium phosphate in the intestine. However, patients with Crigler-Najjar syndrome type 2 who had not been on phototherapy did not have any reduction of serum bilirubin, suggesting that calcium acts by binding photoproducts of bilirubin that are excreted in bile and would have been reabsorbed in the absence of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Orlistat",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study in Gunn rats suggested that combined oral treatment with calcium phosphate plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    was more effective in reducing serum unconjugated bilirubin than phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/41\">",
"     41",
"    </a>",
"    ]. Orlistat, a lipase inhibitor, decreases bilirubin in proportion to the amount of fat excreted in feces supporting the concept that it \"captures\" intestinal unconjugated bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent placebo-controlled crossover trial in humans included 16 patients (seven with type I and nine with type II disease) who were randomly assigned to their usual treatment (phototherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/43\">",
"     43",
"    </a>",
"    ]. In adults, orlistat was initially given at a dose of 120 mg three times daily during a meal, and in children at a dose of 66 mg(2) body surface area three times daily. However, these doses were associated with diarrhea in three patients and one patient had severely increased plasma UCB levels. As a result, the study was modified to use a lower dose: in adults, 60 mg during breakfast and lunch and 120 mg at dinner, and in children, 22",
"    <span class=\"nowrap\">",
"     mg/m(2)",
"    </span>",
"    body surface during breakfast and lunch and 66",
"    <span class=\"nowrap\">",
"     mg/m(2)",
"    </span>",
"    body surface area during dinner. Side effects at this dose were generally mild, temporary, and tolerable for all patients.",
"   </p>",
"   <p>",
"    Compared with placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    was associated with a significant increase in fecal fat and UCB excretion. Plasma UCB concentration decreased by an average of 9 percent; in seven of 16 patients, the decrease in plasma UCB levels was considered to be clinically relevant (ie, &gt;10 percent). Responses were better with lower dietary fat intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Inhibition of bilirubin production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of nonmetabolized \"dead-end\" inhibitors of heme oxygenase, such as tin-protoporphyrin or tin-mesoporphyrin, results in marked inhibition of the enzyme activity in various organs. A single dose of tin-mesoporphyrin administered in neonates, shortly after birth, resulted in an average of 76 percent reduction of serum bilirubin levels and abolished the need for phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, in adult patients with Crigler-Najjar syndrome type 1, the effect is short-lived. Thus, this treatment should be reserved for the treatment of acute emergencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation is considered the only definitive treatment for Crigler-Najjar syndrome type I [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. It rapidly normalizes serum bilirubin levels. Despite its risks, some authorities advocate prophylactic liver transplantation to avoid the risk of kernicterus which, as noted above, may not be fully reversible once it is established [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hepatocyte transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocyte transplantation is a promising alternative to liver transplantation. In experimental studies, the procedure involves infusion of normal hepatocytes into the portal vein [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] or peritoneal space after attachment to microcarrier beads [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/48\">",
"     48",
"    </a>",
"    ]. In a rat model, pretreatment with liver resection and radiation allowed the transplanted cells to proliferate preferentially and correct the metabolic deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/49\">",
"     49",
"    </a>",
"    ]. The liver is the preferred site for long-term survival and function of isolated hepatocytes where, in the absence of immune rejection, they exhibit long-term persistence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/50\">",
"     50",
"    </a>",
"    ]. Hepatocyte transplantation in a patient with Crigler-Najjar syndrome type I resulted in reduction of serum bilirubin levels to approximately 50 percent of pretransplant levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/51\">",
"     51",
"    </a>",
"    ]. However, after nearly three years, serum bilirubin levels started increasing again, and the patient was treated successfully with auxiliary liver transplantation (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31944?source=see_link\">",
"     \"Hepatocyte transplantation\"",
"    </a>",
"    ). Temporary and partial amelioration of hyperbilirubinemia after hepatocyte transplantation was also reported in another recipient with Crigler-Najjar syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Introduction of a normal bilirubin-UGT gene (UGT1A1) has the potential for curing the genetic defect leading to Crigler-Najjar syndrome. Experiments with gene therapy in Gunn rats have been encouraging. As a result, clinical trials in humans are being planned.",
"   </p>",
"   <p>",
"    Introduction of a normal bilirubin-UGT gene can be accomplished by several methods including autologous transplantation of cells that have been transduced with the normal gene ex vivo, and introduction of the gene into the liver by in situ perfusion or by systemic administration of vectors that are capable of carrying the gene to the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ex vivo gene transduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ex vivo gene transduction begins with the harvesting of hepatocytes by partial hepatectomy, which are then grown in primary culture. The cells are transduced with the therapeutic gene by a method that permits stable gene expression and are subsequently reintroduced into the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/53\">",
"     53",
"    </a>",
"    ]. Because the cells are autologous, rejection is not a problem and immunosuppression is not required.",
"   </p>",
"   <p>",
"    This approach with the LDL receptor gene has, in an initial report, produced a modest reduction in LDL-cholesterol in patients with familial hypercholesterolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=see_link\">",
"     \"Treatment of drug-resistant hypercholesterolemia\"",
"    </a>",
"    .) The main shortcoming of this method is that the number of hepatocytes that can be harvested and transduced is limited; furthermore, the surgical resection that is required to harvest the cells is not readily repeatable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vector-mediated gene delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research is underway to develop methods to introduce the normal bilirubin-UGT gene into the liver of Gunn rats using viral and nonviral vectors. Repeated intravenous injection of naked plasmids expressing UGT1A1 delivered the plasmid DNA to muscle cells and reduced serum bilirubin levels in Gunn rats [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/54\">",
"     54",
"    </a>",
"    ]. However, the majority of the ongoing studies are based upon the use of recombinant viral vectors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Adenoviral vectors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviral vectors efficiently deliver the transgene and have the additional advantage of specifically localizing in liver after systemic administration. In contrast to the murine leukemia virus, adenoviral vectors can transfer the transgene into nondividing cells. Unfortunately, the episomal nature of these viruses requires repeated administration, which is not possible because repeated injection induces the host's immune response. Adenoviral vectors, in which all viral genes are deleted, are less immunogenic than the first generation adenovectors. Gene therapy using these vectors has resulted in life-long amelioration of jaundice in Gunn rats [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/55\">",
"     55",
"    </a>",
"    ]. However, it is unlikely that the effect will be long enough to be useful in patients with Crigler-Najjar syndrome. Adenoviral vectors that coexpress UGT1A1 and an inhibitor of immune costimulation (eg, CTLA4Ig) can be administered repeatedly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/54\">",
"     54",
"    </a>",
"    ]. The long-term efficacy and safety of adenovectors in humans have not yet been ascertained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     SV40 and lentiviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant SV40 and recombinant lentiviruses are newer viral vectors that can transfer genes into nondividing cells and integrate into the host genome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/56\">",
"     56",
"    </a>",
"    ]. Unlike adenoviruses, their immunogenicity appears to be negligible. However, they do not localize into the liver after systemic administration and, as a result, need to be administered through the portal vein. Initial results with recombinant SV40 viruses in Gunn rats have been encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Receptor-mediated gene delivery to the liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carrier proteins that deliver systemically administered DNA into the liver have also been used in experiments on Gunn rats [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/58\">",
"     58",
"    </a>",
"    ]. Transgenes introduced in this manner are expressed transiently. The expression can be prolonged to several months by inducing cell proliferation by partial hepatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/59\">",
"     59",
"    </a>",
"    ] or by pharmacological disruption of microtubules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Site-directed gene conversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chimeric RNA-DNA molecules have been used to treat genetic disorders by repairing the responsible mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/61\">",
"     61",
"    </a>",
"    ]. These chimeric molecules are designed to align with specific sequences at the site of the defect responsible for the disease and create a single mismatch. This triggers the host mismatch repair system to correct the mutation. Preliminary Gunn rat experiments with such chimera have shown that the activity of the enzyme can be restored by inserting the missing guanosine residue into the Gunn rat bilirubin-UGT gene ugt1a1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TYPE II DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crigler-Najjar syndrome type II (also known as Arias syndrome) is phenotypically similar to type I disease but the unconjugated hyperbilirubinemia is usually less marked (serum bilirubin &lt;20",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ). The clinical manifestations of this disorder can be illustrated by the original description by Arias in 1962 of eight patients who were between 14 and 52 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/63\">",
"     63",
"    </a>",
"    ]. In contrast to Crigler-Najjar syndrome type I, which is associated with jaundice in the first few days of life, only one-half of the patients were icteric before the age of one year; one patient was 30-years-old before jaundice was noted. Despite the cholestasis, patients do not develop pruritus because serum bile salt levels are normal.",
"   </p>",
"   <p>",
"    The serum bilirubin concentration in these patients ranged from 8 to 18",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Each had reduced hepatic glucuronosyltransferase activities using bilirubin or other compounds as a glucuronide acceptor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/19\">",
"     19",
"    </a>",
"    ]. All patients were clinically normal, apart from icterus, except for a 43-year-old woman with a neurologic syndrome resembling kernicterus who died at the age of 44 years. Autopsy revealed a histologically normal liver. The brain was small and lacked bilirubin staining but demonstrated the typical histology of kernicterus. Several other cases of neurologic involvement in Crigler-Najjar syndrome type II were subsequently described.",
"   </p>",
"   <p>",
"    Bilirubin-UGT activity in the liver in patients with Crigler-Najjar syndrome type II is markedly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/64\">",
"     64",
"    </a>",
"    ]. However, the defect is much less severe than in type I disease (residual bilirubin-UGT activity of 2 to 8 percent). In some cases, the residual hepatic bilirubin-UGT activity measured in vitro in the presence of a high bilirubin substrate concentration may suggest up to 38 percent of normal enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/7\">",
"     7",
"    </a>",
"    ]. However, because of a relatively low affinity of the enzyme for bilirubin, the enzyme is catalytically effective only in the presence of hyperbilirubinemia. Bile is pigmented, but only about 50 percent of the bilirubin produced is conjugated and excreted into the bile [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/19,64\">",
"     19,64",
"    </a>",
"    ]. The major conjugate in Crigler-Najjar syndrome type II is bilirubin monoglucuronide as compared to normal subjects in whom 90 percent of the conjugate is bilirubin diglucuronide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Molecular defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic lesions in Crigler-Najjar syndrome type II, as in type I disease, are located in one of the five exons that code for the bilirubin-UGT (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"UTD.htm?30/51/31536\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. However, in contrast to type I, which can be caused by a variety of mutations, the genetic lesions in type II always consist of point mutations that result in the substitution of a single amino acid which reduces but does not abrogate enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/4\">",
"     4",
"    </a>",
"    ]. The residual enzyme activity is responsible for the partial conjugation of bilirubin and the lesser degree of hyperbilirubinemia.",
"   </p>",
"   <p>",
"    As mentioned above, patients who are compound heterozygotes (having the abnormal promoter of Gilbert's syndrome on one allele plus the abnormal UGT1A1 associated with Crigler-Najjar syndrome type II on the other) have intermediate levels of hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of Crigler-Najjar syndrome type II is unconjugated hyperbilirubinemia, which is usually less than 20",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    but can rise to levels as high as 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    during fasting or intercurrent illness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/66\">",
"     66",
"    </a>",
"    ]. Other liver function tests are normal (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The disease can be distinguished from Crigler-Najjar syndrome type I by its lower levels of hyperbilirubinemia and often by its later age of onset. In addition, hyperbilirubinemia can be reduced by more than 25 percent during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , which presumably works by induction of the residual bilirubin UGT activity (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/19,32\">",
"     19,32",
"    </a>",
"    ]. A response to phenobarbital is not observed in patients with type I disease.",
"   </p>",
"   <p>",
"    For patients in whom the diagnosis is still in question after observing the response to these enzyme-inducing agents, analysis of bile pigments for bilirubin conjugates by chromatographic methods can establish the diagnosis. Conjugated bilirubin is absent or present only in trace amounts in patients with type I who have little or no UGT activity, while a significant amount of conjugated bilirubin is detectable in the bile of patients with type II (although the proportion of monoconjugates is greatly increased) (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ). Genetic testing is currently available only in research laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since patients with Crigler-Najjar syndrome type II are much less likely to develop neurologic consequences than those with type I disease, specific treatment for the hyperbilirubinemia may be unnecessary. However, it may be desirable to treat patients in whom jaundice has impaired quality of life. This can be accomplished by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    (60 to 180 mg daily in divided doses), which reduces serum bilirubin levels by at least 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/19\">",
"     19",
"    </a>",
"    ]. A response should be expected within two to three weeks. A similar benefit can be observed with clofibrate, which is associated with fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/67\">",
"     67",
"    </a>",
"    ]. Successful pregnancy has been described in women with Crigler-Najjar syndrome type II. In some cases, the mother had been treated with phenobarbital [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6201/abstract/68\">",
"     68",
"    </a>",
"    ]. Clofibrate is contraindicated during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2531171\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crigler-Najjar syndrome, also referred to as congenital nonhemolytic jaundice with glucuronosyltransferase deficiency, is a rare, autosomal recessive disorder of bilirubin metabolism. It has been divided into two distinct forms (types I and II) based upon the severity of the disease (",
"      <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Crigler-Najjar syndrome type I should be suspected in infants who develop persistent jaundice due to indirect reacting (unconjugated) bilirubin within the first few days after birth. These children have an otherwise normal liver function test profile and may have neurologic symptoms due to kernicterus. Occasional patients have late onset kernicterus in adolescence. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distinguishing between Crigler-Najjar syndromes type I and II can be difficult. As a general rule, type II is associated with lower serum bilirubin concentrations, although values can overlap with type I, especially when there is underlying hemolysis (",
"      <a class=\"graphic graphic_table graphicRef80818 \" href=\"UTD.htm?27/11/27836\">",
"       table 1",
"      </a>",
"      ). As a result, the differential diagnosis of Crigler-Najjar syndrome type I includes Crigler-Najjar syndrome type II, with or without coexisting hemolysis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Distinction from type II disease'",
"      </a>",
"      above.) The hallmark of Crigler-Najjar syndrome type II is unconjugated hyperbilirubinemia, which is usually less than 20",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      but can rise to levels as high as 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      during fasting or intercurrent illness. Other liver function tests are normal. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Crigler-Najjar syndrome type II are much less likely to develop neurologic consequences than those with type I disease. As a result, specific treatment for the hyperbilirubinemia may be unnecessary. However, it may be desirable to treat patients in whom jaundice has impaired quality of life. Thus, in patients who develop jaundice, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      (60 to 180 mg daily in divided doses in adults and 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      two to three times per day in children), which reduces serum bilirubin levels by at least 25 percent. A response should be expected within two to three weeks. The maintenance dose of phenobarbital needs to be individualized. An equally effective alternative is clofibrate (2 g daily in divided doses in adults), which may be associated with fewer side effects but is contraindicated in pregnancy. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment'",
"      </a>",
"      above.) There is less experience with clofibrate than with phenobarbital in the treatment of Crigler-Najjar syndrome type II. Once the diagnosis is established, it is usually not necessary to continue the enzyme-inducing drugs on a long-term basis.",
"     </li>",
"     <li>",
"      For Crigler-Najjar syndrome type I, phototherapy 8 to 16 hours per day remains the mainstay of treatment. It is important to check regularly the intensity of the fluorescent lamps, which decreases over time. Exposure to sunlight is also an effective form of phototherapy. Oral administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      modestly enhances the hypobilirubinemic effect of phototherapy. Plasmapheresis is reserved for acute increases of serum bilirubin levels or the decline of serum albumin concentrations during intercurrent illness. Liver transplantation remains the definitive therapy and is usually considered around the age of adolescence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112697986\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/1\">",
"      CRIGLER JF Jr, NAJJAR VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 1952; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/2\">",
"      CHILDS B, SIDBURY JB, MIGEON CJ. Glucuronic acid conjugation by patients with familial nonhemolytic jaundice and their relatives. Pediatrics 1959; 23:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/3\">",
"      SZABO L, EBREY P. STUDIES ON THE INHERITANCE OF CRIGLER--NAJJAR'S SYNDROME BY THE MENTHOL TEST. Acta Paediatr Acad Sci Hung 1963; 4:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/4\">",
"      Kadakol A, Ghosh SS, Sappal BS, et al. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/5\">",
"      Maruo Y, Verma IC, Matsui K, et al. Conformational change of UGT1A1 by a novel missense mutation (p.L131P) causing Crigler-Najjar syndrome type I. J Pediatr Gastroenterol Nutr 2008; 46:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/6\">",
"      Sneitz N, Bakker CT, de Knegt RJ, et al. Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Hum Mutat 2010; 31:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/7\">",
"      Seppen J, Bosma PJ, Goldhoorn BG, et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994; 94:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/8\">",
"      Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/9\">",
"      Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994; 269:17960.",
"     </a>",
"    </li>",
"    <li>",
"     Jansen, PL, Bosma, PJ, Roy, Chowdhury, J. Molecular Biology of Bilirubin metabolism. In: Progress Liver Diseases, vol. XIII, Boyer, JL, Ockner, RK (Eds), WB Saunders, Philadelphia 1995. p.125.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/11\">",
"      Erps LT, Ritter JK, Hersh JH, et al. Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro. J Clin Invest 1994; 93:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/12\">",
"      Chalasani N, Chowdhury NR, Chowdhury JR, Boyer TD. Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect. Gastroenterology 1997; 112:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/13\">",
"      Kadakol A, Sappal BS, Ghosh SS, et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet 2001; 38:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/14\">",
"      Gunn CH. Hereditary acholuric jaundice in a new mutant strain of rats. J Hered 1938; 29:137.",
"     </a>",
"    </li>",
"    <li>",
"     Roy Chowdhury J, Van Es HH, Roy Chowdhury N, Gunn rat. An animal model of deficiency of bilirubin conjugation. In: Hepatic Transport and Bile Secretion, Physiology and Pathophysiology, Tavoloni N, Berk PD (Eds), Raven, New York 1992. p.713.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/16\">",
"      SCHMID R, AXELROD J, HAMMAKER L, SWARM RL. Congenital jaundice in rats, due to a defect in glucuronide formation. J Clin Invest 1958; 37:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/17\">",
"      Blaschke TF, Berk PD, Scharschmidt BF, et al. Crigler-Najjar syndrome: an unusual course with development of neurologic damage at age eighteen. Pediatr Res 1974; 8:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/18\">",
"      Sleisenger MH. Nonhemolytic unconjugated hyperbilirubinemia with hepatic glucuronyl transferase deficiency: a genetic study in four generations. Trans Assoc Am Physicians 1967; 80:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/19\">",
"      Arias IM, Gartner LM, Cohen M, et al. Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am J Med 1969; 47:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/20\">",
"      Berk PD, Martin JF, Blaschke TF, et al. Unconjugated hyperbilirubinemia. Physiologic evaluation and experimental approaches to therapy. Ann Intern Med 1975; 82:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/21\">",
"      Kapitulnik J, Kaufmann NA, Goitein K, et al. A pigment found in Crigler--Najjar syndrome and its similarity to an ultrafiltrable photoderivative of bilirubin. Clin Chim Acta 1974; 57:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/22\">",
"      Moscowitz A, Weimer M, Lightner DA, et al. The in vitro conversion of bile pigments to the urobilinoids by a rat clostridia species as compared with the human fecal flora. 3. Natural d-urobilin, synthetic i-urobilin, and synthetic i-urobilinogen. Biochem Med 1971; 4:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/23\">",
"      BILLING BH, GRAY CH, KULCZYCKA A, et al. THE METABOLISM OF (14C)-BILIRUBIN IN CONGENITAL NON-HAEMOLYTIC HYPERBILIRUBINAEMIA. Clin Sci 1964; 27:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/24\">",
"      NOVIKOFF AB, ESSNER E. The liver cell. Some new approaches to its study. Am J Med 1960; 29:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/25\">",
"      Maisels MJ. Neonatal jaundice. Semin Liver Dis 1988; 8:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/26\">",
"      Maruo Y, Nishizawa K, Sato H, et al. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 1999; 103:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/27\">",
"      Maisels MJ, Gifford K. Normal serum bilirubin levels in the newborn and the effect of breast-feeding. Pediatrics 1986; 78:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/28\">",
"      Grunebaum E, Amir J, Merlob P, et al. Breast mild jaundice: natural history, familial incidence and late neurodevelopmental outcome of the infant. Eur J Pediatr 1991; 150:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/29\">",
"      Kadakol A, Deocharan B, Mukhopadhyay L, et al. Rapid prenatal diagnosis of Crigler-Najjar syndrome type 1 by genetic analysis of chorionic villus samples (abstract). Hepatology 1998; 28:316A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/30\">",
"      Wolkoff AW, Chowdhury JR, Gartner LA, et al. Clinical conference. Crigler-Najjar syndrome (type I) in an adult male. Gastroenterology 1979; 76:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/31\">",
"      BERENDSOHN S, LOWMAN J, SUNDBERG D, WATSON CJ. IDIOPATHIC DYSERYTHROPOIETIC JAUNDICE. Blood 1964; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/32\">",
"      van der Veere CN, Sinaasappel M, McDonagh AF, et al. Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology 1996; 24:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/33\">",
"      Sokal EM, Silva ES, Hermans D, et al. Orthotopic liver transplantation for Crigler-Najjar type I disease in six children. Transplantation 1995; 60:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/34\">",
"      Itoh S, Onishi S. Kinetic study of the photochemical changes of (ZZ)-bilirubin IX alpha bound to human serum albumin. Demonstration of (EZ)-bilirubin IX alpha as an intermediate in photochemical changes from (ZZ)-bilirubin IX alpha to (EZ)-cyclobilirubin IX alpha. Biochem J 1985; 226:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/35\">",
"      Pett S, Mowat AP. Crigler-Najjar syndrome types I and II. Clinical experience--King's College Hospital 1972-1978. Phenobarbitone, phototherapy and liver transplantation. Mol Aspects Med 1987; 9:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/36\">",
"      Lund HT, Jacobsen J. Influence of phototherapy on the biliary bilirubin excretion pattern in newborn infants with hyperbilirubinemia. J Pediatr 1974; 85:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/37\">",
"      Gajdos V, Petit F, Trioche P, et al. Successful pregnancy in a Crigler-Najjar type I patient treated by phototherapy and semimonthly albumin infusions. Gastroenterology 2006; 131:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/38\">",
"      Ahmed P, Pratt A, Land VJ, et al. Multiple plasma exchanges successfully maintain a young adult patient with Crigler-Najjar syndrome type I. J Clin Apher 1989; 5:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/39\">",
"      Van Der Veere CN, Schoemaker B, Bakker C, et al. Influence of dietary calcium phosphate on the disposition of bilirubin in rats with unconjugated hyperbilirubinemia. Hepatology 1996; 24:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/40\">",
"      Van der Veere CN, Jansen PL, Sinaasappel M, et al. Oral calcium phosphate: a new therapy for Crigler-Najjar disease? Gastroenterology 1997; 112:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/41\">",
"      Hafkamp AM, Havinga R, Sinaasappel M, Verkade HJ. Effective oral treatment of unconjugated hyperbilirubinemia in Gunn rats. Hepatology 2005; 41:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/42\">",
"      Nishioka T, Hafkamp AM, Havinga R, et al. Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats. J Pediatr 2003; 143:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/43\">",
"      Hafkamp AM, Nelisse-Haak R, Sinaasappel M, et al. Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial. Pediatr Res 2007; 62:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/44\">",
"      Valaes T, Petmezaki S, Henschke C, et al. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. Pediatrics 1994; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/45\">",
"      Kappas A, Drummond GS, Henschke C, Valaes T. Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns. Pediatrics 1995; 95:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/46\">",
"      Vroemen JP, Blanckaert N, Buurman WA, et al. Treatment of enzyme deficiency by hepatocyte transplantation in rats. J Surg Res 1985; 39:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/47\">",
"      Ilan Y, Roy-Chowdhury N, Prakash R, et al. Massive repopulation of rat liver by transplantation of hepatocytes into specific lobes of the liver and ligation of portal vein branches to other lobes. Transplantation 1997; 64:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/48\">",
"      Demetriou AA, Whiting JF, Feldman D, et al. Replacement of liver function in rats by transplantation of microcarrier-attached hepatocytes. Science 1986; 233:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/49\">",
"      Guha C, Parashar B, Deb NJ, et al. Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection. Hepatology 2002; 36:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/50\">",
"      Gupta S, Aragona E, Vemuru RP, et al. Permanent engraftment and function of hepatocytes delivered to the liver: implications for gene therapy and liver repopulation. Hepatology 1991; 14:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/51\">",
"      Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/52\">",
"      Ambrosino G, Varotto S, Strom SC, et al. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant 2005; 14:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/53\">",
"      Tada K, Roy-Chowdhury N, Prasad V, et al. Long-term amelioration of bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified immortalized autologous hepatocytes. Cell Transplant 1998; 7:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/54\">",
"      Jia Z, Dank&oacute; I. Long-term correction of hyperbilirubinemia in the Gunn rat by repeated intravenous delivery of naked plasmid DNA into muscle. Mol Ther 2005; 12:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/55\">",
"      Toietta G, Mane VP, Norona WS, et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 2005; 102:3930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/56\">",
"      Parashar B, Ghosh S, Kadakol A, et al. Recombinant simian virus 40 vectors integrate into host genome, and permit efficient, long-term and repeatable gene transfer to the liver in vivo (abstract). Hepatology 1999; 30:298A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/57\">",
"      Sauter BV, Parashar B, Chowdhury NR, et al. A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats. Gastroenterology 2000; 119:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/58\">",
"      Wilson JM, Grossman M, Wu CH, et al. Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. J Biol Chem 1992; 267:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/59\">",
"      Chowdhury NR, Wu CH, Wu GY, et al. Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. Prolonged persistence in cytoplasmic vesicles after partial hepatectomy. J Biol Chem 1993; 268:11265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/60\">",
"      Bommineni VR, Chowdhury NR, Wu GY, et al. Depolymerization of hepatocellular microtubules after partial hepatectomy. J Biol Chem 1994; 269:25200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/61\">",
"      Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med 1998; 4:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/62\">",
"      Kren BT, Parashar B, Bandyopadhyay P, et al. Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci U S A 1999; 96:10349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/63\">",
"      ARIAS IM. Chronic unconjugated hyperbilirubinemia without overt signs of hemolysis in adolescents and adults. J Clin Invest 1962; 41:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/64\">",
"      Gordon ER, Shaffer EA, Sass-Kortsak A. Bilirubin secretion and conjujation in the Crigler-Najjar syndrome type II. Gastroenterology 1976; 70:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/65\">",
"      Fevery J, Blanckaert N, Heirwegh KP, et al. Unconjugated bilirubin and an increased proportion of bilirubin monoconjugates in the bile of patients with Gilbert's syndrome and Crigler-Najjar disease. J Clin Invest 1977; 60:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/66\">",
"      Gollan JL, Huang SN, Billing B, Sherlock S. Prolonged survival in three brothers with severe type 2 Crigler-Najjar syndrome. Ultrastructural and metabolic studies. Gastroenterology 1975; 68:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/67\">",
"      Gabilan JC, Benattar C, Lindenbaum A. Clofibrate treatment of neonatal jaundice. Pediatrics 1990; 86:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6201/abstract/68\">",
"      Passuello V, Puhl AG, Wirth S, et al. Pregnancy outcome in maternal Crigler-Najjar syndrome type II: a case report and systematic review of the literature. Fetal Diagn Ther 2009; 26:121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3569 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6201=[""].join("\n");
var outline_f6_3_6201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2531171\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPE I DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Molecular defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Distinction from type II disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Calcium phosphate supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Orlistat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Inhibition of bilirubin production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hepatocyte transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ex vivo gene transduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vector-mediated gene delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Adenoviral vectors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - SV40 and lentiviruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Receptor-mediated gene delivery to the liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Site-directed gene conversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TYPE II DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Molecular defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2531171\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112697986\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3569\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3569|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/51/31536\" title=\"figure 1\">",
"      Bilirubin in hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/44/33487\" title=\"figure 2\">",
"      UGT gene locus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3569|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/11/27836\" title=\"table 1\">",
"      Inherited uncong hyperbili",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31944?source=related_link\">",
"      Hepatocyte transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=related_link\">",
"      Treatment of drug-resistant hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6202="Renal manifestations of sickle cell disease";
var content_f6_3_6202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal manifestations of sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6202/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6202/contributors\">",
"     Edgar V Lerma, MD, FACP, FASN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6202/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6202/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/3/6202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/3/6202/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/3/6202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of sickle cell disease. The polymerization of deoxy hemoglobin S results in distortion of the red blood cell into the classic sickle shape and a marked decrease in red cell deformability, and is the primary cause of vaso-occlusive phenomena [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent changes in red cell membrane structure and function, disordered cell volume control, and increased adherence to vascular endothelium also play an important role [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaso-occlusion results in recurrent painful episodes and a variety of serious organ system complications that can lead to life-long disabilities and even death. The renal manifestations of sickle cell disease will be reviewed here. The other manifestations, diagnosis and management of this disorder, and other sickle cell syndromes, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant renal involvement occurs more frequently in sickle cell disease than in sickle cell trait or in combined hemoglobinopathies, with the exception of renal medullary carcinoma, which appears to be more common among patients with sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Renal infarcts and papillary necrosis occur in either sickle cell disease or trait, with prevalence estimates of 30 to 40 percent in radiographic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with sickle cell disease, the prevalence of proteinuria has been estimated to be 20 to 25 percent, and decreased kidney function has been reported in 5 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Among patients with other sickling hemoglobinopathies, albuminuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria has been reported in 8 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/12-14\">",
"     12-14",
"    </a>",
"    ] (with the prevalence increasing with age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/12\">",
"     12",
"    </a>",
"    ]), and decreased kidney function in six percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, sickle cell disease accounts for &lt;1 percent of all new cases of end stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/15\">",
"     15",
"    </a>",
"    ]. The incidence of renal failure in patients with sickle cell disease was best described in two related cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 25-year observational study of 725 patients with sickle cell disease (most of them children), 31 (4 percent) developed renal failure (defined as an irreversible rise in serum creatinine concentration) at a median age of 23 years, most of whom progressed to requiring dialysis within a few years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/4\">",
"       4",
"      </a>",
"      ]. Patients with hypertension, nephrotic-range proteinuria, hematuria, severe anemia, and hyperfiltration were more likely to progress to renal failure.",
"     </li>",
"     <li>",
"      This cohort was extended another 15 years with additional enrollment totaling 1056 patients (with a median age of 20 years at the start of follow-up) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/5\">",
"       5",
"      </a>",
"      ]. Twelve percent developed renal failure at a median age of 37 years. The higher rate and older age at the development of renal failure compared with the earlier report may reflect the addition of older patients to the cohort and extension of the observation period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain genetic factors, such as polymorphisms in the myosin heavy chain 9 (MHY9) and apolipoprotein L1 (APOL1) genes, are associated with a higher risk of proteinuria and reduced glomerular filtration rate in patients with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/16\">",
"     16",
"    </a>",
"    ]. These genes are also associated with kidney disease in black patients without sickle cell disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sickle cell variants and other hemoglobinopathies may also be associated with kidney disease. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 40-year observation of 284 patients with SC disease (mean age of 21 years at the onset of follow-up), 2.8 percent developed renal failure at a mean age of 51 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sickle",
"      <span class=\"nowrap\">",
"       cell/beta",
"      </span>",
"      thalassemia compound heterozygotes also exhibit progressive renal failure, but the incidence is not well described [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/14,17\">",
"       14,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=see_link\">",
"       \"Variant sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both sickle cell trait (15 versus 7 percent) and hemoglobin C trait (5 versus 2 percent) were significantly more common in African-Americans with end-stage renal disease compared with African-Americans in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival is decreased in patients with sickle cell disease who develop renal failure. In the previously cited observational study, survival in patients with end-stage renal disease was on average only four years after the diagnosis of renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/4\">",
"     4",
"    </a>",
"    ]. Median survival among patients with and without renal failure was 29 and 51 years, respectively. The mortality risk of patients with renal failure was similar to those who had had a stroke.",
"   </p>",
"   <p>",
"    Compared to patients with renal failure who do not have sickle cell disease, survival is substantially decreased among patients with renal failure and sickle cell disease, whether treated with dialysis or transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RENAL PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal biopsy in early sickle cell nephropathy reveals glomerular hypertrophy, hemosiderin deposits, focal areas of hemorrhage or necrosis, and in later stages, interstitial inflammation, edema, fibrosis, tubular atrophy, and papillary infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/11,20-22\">",
"     11,20-22",
"    </a>",
"    ]. The later changes are mostly due to vascular dropout (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52364 \" href=\"UTD.htm?42/12/43202\">",
"     image 1",
"    </a>",
"    ). In patients who reach end stage renal disease due to sickle cell disease, renal biopsy shows glomerular enlargement and focal segmental glomerulosclerosis (FSGS) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/11\">",
"     11",
"    </a>",
"    ], with the perihilar variant being most frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/11,23\">",
"     11,23",
"    </a>",
"    ]. A collapsing form of FSGS has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=see_link\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histopathologically, the papillary necrosis associated with sickle cell disease can be differentiated from that associated with analgesic nephropathy. The former shows destruction of the vasa rectae, and vascular congestion of the collecting ducts, inner medulla and papillae. In analgesic nephropathy, vasa rectae are less often involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27318?source=see_link\">",
"     \"Clinical manifestations and diagnosis of analgesic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less often, membranoproliferative glomerulonephritis (MPGN) with mesangial expansion and basement membrane duplication may be seen, either as an isolated finding or in association with focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It has been proposed that this form of MPGN is caused by fragmented RBCs lodged in isolated capillary loops and phagocytosed by mesangial cells, stimulating expansion of the mesangium and new basement membrane deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/21,26\">",
"     21,26",
"    </a>",
"    ]. The particular absence of immune complexes and electron dense deposits differentiates this from idiopathic MPGN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary event appears to be sickling of erythrocytes in the vasa recta capillaries in the medulla, leading to microthrombotic infarction and extravasation of blood in the medulla. Sickling is promoted by the normal medullary environment: low oxygen tension, low pH, and high osmolality (which pulls water out of the red cells, thereby increasing the concentration of hemoglobin S). The increased blood viscosity contributes to ischemia and infarction in the renal microcirculation. More severe occlusions can lead to renal infarcts and papillary necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link&amp;anchor=H6#H6\">",
"     \"Chapter 4A: Cell model for loop of Henle transport\", section on 'Passive Na+ reabsorption and medullary hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glomerular ischemia appears to promote increased renal blood flow and glomerular filtration rate (GFR). This is thought to be mediated primarily by vasodilator prostaglandins released presumably to reverse the medullary ischemia, since it can be reversed by the administration of a nonsteroidal antiinflammatory drug [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Studies in transgenic mice suggest that increased glomerular nitric oxide synthesis also may contribute to the glomerular hyperfiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/21,30\">",
"     21,30",
"    </a>",
"    ]. In addition, there is glomerular hypertrophy contributing to a GFR that is preserved despite nephron damage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a correlation between glomerular hyperfiltration and chronic hemolysis. It has been suggested that this is due to increased cardiac output and a hemolysis-mediated increase in vascular tone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive renal failure (glomerulosclerosis) occurs due to continued glomerular ischemia; microangiopathic studies have demonstrated that the vasa recta are almost completely lost in older patients with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. Endothelin-1 (ET-1), stimulated by glomerular hypoxia, may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional contributors include secondary hemodynamic injury induced by the intraglomerular hypertension and hypertrophy that drive the initial hyperfiltration, and additional insults such as analgesic nephropathy secondary to consumption of large doses of analgesics. [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/20,33,34\">",
"     20,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27318?source=see_link\">",
"     \"Clinical manifestations and diagnosis of analgesic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RENAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structural consequences of sickled red blood cells in the renal circulation lead to the myriad renal manifestations seen in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/3,28,35\">",
"     3,28,35",
"    </a>",
"    ]. As previously mentioned, these manifestations are generally less common or less severe in patients with sickle cell trait, with the exception of renal medullary carcinoma, which appears to be more frequent among patients with sickle cell trait. The age at presentation of the various manifestations of renal disease varies widely (",
"    <a class=\"graphic graphic_figure graphicRef68540 \" href=\"UTD.htm?28/48/29453\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless microscopic or gross hematuria (due to papillary infarcts) is a common complaint that is also seen in patients with sickle trait. The renal bleeding is typically mild, unilateral (and predominantly left-sided), and self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/21\">",
"     21",
"    </a>",
"    ]. The predominant left-sided origin of the hematuria has been attributed to the greater length of the left renal vein and the \"nutcracker phenomenon.\" The compression of the left renal vein between the aorta and superior mesenteric artery leads to increased blood pressure in the vein, thereby further increasing relative anoxia in the renal medulla, which promotes sickling [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renal infarction and papillary necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;More severe ischemia can lead to renal infarcts and papillary necrosis. Papillary necrosis commonly presents as painless gross hematuria, and may be complicated by urinary tract infection or obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]. Acute segmental or total renal infarcts may present with nausea, vomiting, flank or abdominal pain, fever and presumably renin-mediated hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11367?source=see_link\">",
"     \"Diagnosis and treatment of renal infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diminished concentrating ability",
"    </span>",
"    &nbsp;&mdash;&nbsp;An impairment in concentrating ability (hyposthenuria), leading to nocturia and polyuria, is an early and universal finding in sickle cell disease, and is less severe and occurs later in the course of patients with sickle cell trait and SC disease. Sickling in the vasa rectae presumably interferes with countercurrent exchange in the inner medulla, thereby leading to impairment of free water reabsorption. This defect is reversible by blood transfusions below the age of 10 but is irreversible in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/39\">",
"     39",
"    </a>",
"    ]. The net effect is that the maximum urine osmolality at age 10 is only 400 to 450",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    as compared to 900 to 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in normals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, both antidiuretic hormone generation and urinary diluting capacity remain unperturbed in patients with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/40\">",
"     40",
"    </a>",
"    ]. The preservation of normal urinary diluting capacity is a result of intact reabsorptive function of the superficial loops of Henle of the cortical nephrons, which are supplied by peritubular capillaries and not the maximally affected vasa rectae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=see_link\">",
"     \"Chapter 4B: Countercurrent mechanism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2886?source=see_link\">",
"     \"Chapter 9B: Renal water excretion and reabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired distal hydrogen and potassium secretion can lead to an incomplete form of distal renal tubular acidosis, which can be associated with aldosterone independent hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Although the exact mechanism is not clear, medullary blood flow disturbance and hypoxia may lead to insufficient energy to maintain the hydrogen ion and electrochemical gradients along the collecting ducts. However, these impairments are usually mild, and become clinically apparent only if there is a complicating factor such as potassium or acid loading, intravascular volume depletion, or during rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/28,35\">",
"     28,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Abnormal proximal tubular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;For reasons that are unclear, proximal tubular function is supranormal in sickle cell disease. This may be manifested both by hyperphosphatemia (due to increased phosphate reabsorption) and by an elevated creatinine clearance (due to enhanced creatinine secretion) in relation to the true GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/28,35,43\">",
"     28,35,43",
"    </a>",
"    ]. In one study, for example, the creatinine clearance overestimated the GFR by 29 percent (154 versus 119",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    roughly twice the percent difference in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/29\">",
"     29",
"    </a>",
"    ]. The Schwartz formula was designed to minimize such inaccuracy in estimating GFR, however, it is not without limitations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Serum creatinine and GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum cystatin C may be a more sensitive indicator of renal decline compared to serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further clinical studies need to be performed to compare measured GFR with that estimated using various formulas among patients with sickle cell nephropathy.",
"   </p>",
"   <p>",
"    There is also increased secretion of uric acid in patients with sickle cell disease.",
"   </p>",
"   <p>",
"    Proximal tubule dysfunction is generally observed in younger patients with sickle cell disease and may be independent of glomerular damage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of potential etiologies for acute kidney injury (AKI) among patients with sickle cell disease. As a result of impaired concentrating ability, they are predisposed to prerenal failure secondary to intravascular volume depletion. Intrinsic renal causes of AKI include rhabdomyolysis, sepsis, drug nephrotoxicity, renal vein thrombosis, and even hepatorenal syndrome (hemosiderosis-induced hepatic failure). Postrenal causes include urinary tract obstruction secondary to blood clots, and less commonly, papillary necrosis. The prognosis appears to be favorable, with one small study reporting a rate of recovery of 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, the incidence of AKI during vaso-occlusive crises or episodes was surprisingly low (&lt;5 percent), and appeared to be limited to those with acute coronary syndrome and pulmonary hypertension, suggesting a potential role for right ventricular dysfunction and venous congestion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/47\">",
"     47",
"    </a>",
"    ]. However, a higher incidence of AKI (10 percent) was reported in another study of hospitalized patients with SC disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/46\">",
"     46",
"    </a>",
"    ]. Such wide variation in results could probably be due to differing criteria used to define AKI and its timing of onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Progressive renal failure and proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with renal disease due to sickle cell disease, the glomerular filtration rate (GFR) and renal blood flow are greater than normal in young patients, below normal in patients over the age of 30, and may progressively fall thereafter, leading to end-stage renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/3,27-29,34,35,48\">",
"     3,27-29,34,35,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive decline in GFR is often associated with increasing proteinuria and evidence of glomerular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/4,11,20,49\">",
"     4,11,20,49",
"    </a>",
"    ]. This course is different from the acute onset of the nephrotic syndrome typically seen in idiopathic primary focal segmental glomerulosclerosis and minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, acute onset of nephrosis suggests that sickle cell disease is not the cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less often, patients with sickle cell disease develop the nephrotic syndrome due to membranoproliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/25\">",
"     25",
"    </a>",
"    ]. This may be related to a direct effect of sickled RBC, but patients may also have MPGN associated with hepatitis C infection acquired from multiple blood transfusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the nephropathy associated with sickle cell disease, it is also possible that the medullary ischemia induced by sickling can exacerbate the course of other underlying renal diseases. There is, for example, some evidence that black patients with sickle cell trait and autosomal dominant polycystic kidney disease develop end-stage renal disease earlier than those without sickle hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Renal medullary carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal medullary carcinoma is a highly aggressive malignancy found almost exclusively in young black patients with sickle cell trait, and less commonly, sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/3,7,51,52\">",
"     3,7,51,52",
"    </a>",
"    ]. Most patients are younger than 20 years of age at presentation, and there appears to be a male predominance in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/7,51,52\">",
"     7,51,52",
"    </a>",
"    ]. Genetic linkage is suggested by the young age and tumor aggressiveness, and cytogenetic testing has suggested a potential association with various chromosomal anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients present with gross hematuria, urinary tract infection, flank pain, an abdominal mass,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Metastatic disease is commonly present at diagnosis, thus surgical resection is not curative. There is very limited experience treating disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/7,52,54\">",
"     7,52,54",
"    </a>",
"    ], and the prognosis is dismal; survival after diagnosis is usually less than 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/7,52,54\">",
"     7,52,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=see_link&amp;anchor=H350648051#H350648051\">",
"     \"Overview of the treatment of renal cell carcinoma\", section on 'Nonclear cell RCC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, hematuria should prompt evaluation for this type of malignancy, particularly among younger patients with sickle cell disease or trait. Imaging (usually CT scan and intravenous pyelography) demonstrates a centrally located infiltrative lesion invading the renal sinus with peripheral caliectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    to treat sickle cell disease has raised concern that these patients may have an increased risk of other cancers, but this is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired immunity secondary to autosplenectomy, and consequent opsonic antibody deficiency, predisposes patients with sickle cell disease to infections by encapsulated organisms, including urinary tract infections (UTI) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/3\">",
"     3",
"    </a>",
"    ]. An additional predisposing factor to UTI is papillary necrosis.",
"   </p>",
"   <p>",
"    UTI, as other infections, can precipitate a sickle cell crisis. This is particularly important in the pediatric population, most of whom do not complain of typical urinary tract symptoms (eg, urgency, frequency, dysuria). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hypertension among patients with sickle cell disease is markedly lower than observed in the general black population (2 to 6 percent versus 28 percent, respectively), and some patients may have lower than normal blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/3,59\">",
"     3,59",
"    </a>",
"    ]. Proposed mechanisms for this relative hypotension include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium and water wasting due to the medullary defect [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/28,59\">",
"       28,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic vasodilatation compensating for microcirculatory flow disturbances [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased production of prostaglandins and nitric oxide [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced vascular reactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations have important clinical implications. These include the possibilities that relatively \"normal\" blood pressure levels actually represent significant hypertension with attendant risks of adverse cardiovascular outcomes, and that severe hypotension may ensue with the use antihypertensive agents to lower intraglomerular pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of renal disease due to sickle cell disease is primarily based on recognition of the associated clinical manifestations, and is largely a diagnosis of exclusion. The diagnosis of sickle cell disease is discussed in detail elsewhere. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Renal manifestations'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient suspected of having sickle cell disease-associated renal disease should have the following tests performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinalysis with microscopy and quantitation of total proteinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"       \"Urinalysis in the diagnosis of kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estimation of kidney function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal ultrasound, which can exclude other abnormalities such as renal stones, and can demonstrate papillary necrosis. With ultrasonography, there is increased echogenicity of the inner medulla, and in more advanced cases, a filling defect in the area of the medullary tip can be seen. Intravenous pyelography (IVP) is more definitive (",
"      <a class=\"graphic graphic_figure graphicRef52169 \" href=\"UTD.htm?37/61/38879\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74530 \" href=\"UTD.htm?2/15/2303\">",
"       image 2",
"      </a>",
"      ). In the patient presenting with hematuria, a CT scan should also be done to evaluate for renal medullary carcinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis C and HIV testing, since they are at increased risk for these and other transfusion-associated infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"       \"Epidemiology and transmission of hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"       \"Transfusion transmitted HIV infection and AIDS\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"       \"Transfusion transmitted bacterial infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A renal biopsy is rarely required to establish the diagnosis, but may be necessary in the patient with massive proteinuria or rapidly progressive renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Early detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early detection of patients with or at risk for kidney involvement may enable us to delay the progression of kidney disease. The following methods for detection are under study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal Doppler sonography resistive index (RI) and pulsatility index (PI) values may provide early radiologic predictors of renovascular changes in sickle cell disease. An increase in both RI and PI indices in sickle cell patients is believed to be the result of the increased vascular tone due to vaso-occlusive mechanisms such as vascular intimal hyperplasia, thrombosis, altered vascular reactivity, and vasopressin [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early markers of renal damage in patients with sickle cell disease that are under investigation include serum cystatin C (Cys-C), urine N-acetyl-Beta-D-glucosaminidase (NAG), and urinary Beta2-microglobulin (Beta2-M) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The excretion rate of active kallikrein has been shown to have a directly positive yet independent correlation with the log AER (albumin excretion rate) in children with SCD, thereby suggesting its potential role as a marker for progressive nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, urinary and plasma endothelin-1 (ET-1) levels were demonstrated to be elevated in patients with SC disease, as compared with carefully matched controls. Furthermore, the urine ET-1 excretion also correlated not only with a marked urinary concentrating defect, but also microalbuminuria in patients on dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study involving 40 patients with SC disease (ages 5 to 19), univariate analyses showed a significant correlation between LDH level and microalbuminuria (Pearson r = 0.47, p = 0.04) and between the LDH level and proteinuria (Pearson r = 0.48, p = 0.035). Multivariate analyses showed a significant correlation between microalbuminuria and LDH level (p = 0.04) when adjusted for age, gender, estimated GFR, hemoglobin level, hemoglobin F percent, type of SC anemia, BMI, history of blood transfusions, and reticulocyte count [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A cross-sectional analysis for nephropathy in patients with SC disease, interestingly showed a &ldquo;distinct&rdquo; biomarker pattern: kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL) had a very strong correlation with albuminuria in this patients. Surprisingly, and interestingly, NGAL, liver-type fatty acid binding protein (L-FABP) and transforming growth factor-&beta;1 (TGF-&beta;) did not show any correlation with albuminuria in patients with SC disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more comprehensive discussion of the general approach to the patient with acute and chronic kidney disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement in patients with sickle cell disease can be due to causes other than sickle cell disease. These should be carefully considered based on the patient's family and clinical history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are the most common renal manifestations that may be due to non-sickle cell disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute tubular necrosis due to hemodynamic insults or toxins.",
"     </li>",
"     <li>",
"      MPGN due to hepatitis C virus.",
"     </li>",
"     <li>",
"      Obstruction, eg, caliectasis, due to papillary necrosis or nephrolithiasis.",
"     </li>",
"     <li>",
"      Papillary necrosis may also be caused by interstitial nephritis, acute pyelonephritis, obstructive uropathy, diabetes mellitus, or analgesic abuse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to its self-limited nature, conservative measures such as bed rest are recommended, to avoid dislodging blood clots. There are case reports and case series of treatment of more severe cases via one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydration using alkaline fluids, with diuretics as needed to increase urine flow rate [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/65,66\">",
"       65,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blood transfusion to lower the concentration of hemoglobin S.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe and refractory hematuria can rarely occur, and the following different approaches have been tried, although none is well studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several patients have been successfully treated with oral urea in doses high enough to raise the BUN to 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (36",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or higher [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/67\">",
"       67",
"      </a>",
"      ]. Urea presumably acts by inhibiting the gelation of deoxygenated sickle hemoglobin. This approach may be preferred as may be least associated with adverse consequences.",
"     </li>",
"     <li>",
"      Administration of vasopressin [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with hyperactive fibrinolysis who have severe, prolonged hematuria, administration of epsilon-aminocaproic acid (EACA) can diminish hematuria [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. There is, however, a risk of urinary tract obstruction due to the formation of blood clots within the collecting system [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/71\">",
"       71",
"      </a>",
"      ]. As a result, antifibrinolytic therapy should be considered only when all other modalities have failed.",
"     </li>",
"     <li>",
"      Angiographic localization followed by embolization of the involved renal vessel or balloon tamponade for bleeding due to papillary necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/72\">",
"       72",
"      </a>",
"      ]. Unilateral nephrectomy has been performed, but is not recommended, since bleeding can recur in the contralateral kidney.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Progression of CKD and hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not well established, modalities aimed at lowering the intraglomerular pressure may be beneficial in patients with progressive renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Angiotensin converting enzyme [ACE] inhibitors (or angiotensin II receptor blockers [ARB]) can lower protein excretion by more than 50 percent in these patients, and should be provided even in the absence of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/11,75\">",
"     11,75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Blood pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the patient has proteinuria (greater than 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    the blood pressure goal is less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg. There is no clear evidence of benefit from this goal in patients with CKD and lower rates of protein excretion. If an ACE or ARB is insufficient for blood pressure control, agents other than diuretics should be added, since diuretics can cause intravascular volume depletion that may precipitate SC crises. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    to an ACE or ARB may lead to further reduction of proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonsteroidal anti-inflammatory drugs (NSAIDs) also prevent hyperfiltration. However, they are not recommended because they also reduce renal plasma flow and glomerular filtration rate in SCD patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal hemoglobin for patients with sickle cell anemia is lower than that for patients with anemia related only to chronic kidney disease. One recommendation is to maintain a hemoglobin concentration not higher than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (hematocrit 30 percent) with blood transfusions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythropoietin, and avoiding a hematocrit rise of greater than 1 to 2 percent per week [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Higher hemoglobin levels or a faster rise in hematocrit can precipitate a vaso-occlusive crisis.",
"   </p>",
"   <p>",
"    The role of exogenously administered erythropoietin (EPO) in the routine management of anemia in patients with sickle cell disease and kidney failure is uncertain. Some patients benefit from blood transfusions to increase the proportion of HbA, whereas EPO, if used, does not have this beneficial effect. If used, standard CKD doses of EPO may be used (target hemoglobin 10",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    although patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    may require higher doses given the bone marrow suppressive effect of this agent.",
"   </p>",
"   <p>",
"    The management of patients with sickle cell anemia is discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link\">",
"     \"Specific therapies for sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the various modes of renal replacement therapy available, most patients with end-stage renal disease due to sickle cell disease appear to be treated with hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hemodialysis related complications does not appear to be different in patients with sickle cell disease when compared to the general population, although survival appears to be diminished [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/81\">",
"     81",
"    </a>",
"    ]. In a study using data from the United States Renal Data System (USRDS), among 397 incident dialysis patients with sickle cell disease, two-year mortality was similar to that of patients without sickle cell disease (33 and 37 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/15\">",
"     15",
"    </a>",
"    ]. However, patients with sickle cell disease were substantially younger at initiation of dialysis (mean age 40 versus 60 years). In the same study, an age-matched analysis of patients with a mean age of 35 years demonstrated a greater difference in survival (60 versus 80 percent at three years and 40 versus 70 percent at five years, for patients with and without sickle cell nephropathy, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be a lower rate of wait-listing for transplantation (7 versus 11 per 100 patient years) and of transplantation (2.6 versus 6.8 per 100 patient years), among patients with sickle cell disease compared to patients without sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/15\">",
"     15",
"    </a>",
"    ]. Potential explanations for lower rates of transplantation, other than possible racial bias as in the general population, include high levels of panel reactive antibody due to numerous blood transfusions, and concerns about a higher infection risk given their already immunocompromised state (autosplenectomy), increased risk of avascular necrosis due to steroids and contributing to sickle cell crisis (attributed to the partial correction of anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether survival is improved compared to dialysis is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/19,82-85\">",
"     19,82-85",
"    </a>",
"    ]. Using data from the USRDS, the outcomes of 82 sickle cell patients were compared to 22,500 African-American transplant recipients without the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/19\">",
"     19",
"    </a>",
"    ]. Although graft survival at one year was comparable in the two groups (78 percent), patient survival was lower among patients with sickle cell disease (78 versus 90 percent at one year and 59 versus 81 percent at three years, for patients with and without sickle cell disease). The reported survival of patients with sickle cell disease who received a transplant was similar to that of dialysis patients in the previously mentioned study (both approximately 60 percent at three years).",
"   </p>",
"   <p>",
"    Recurrent disease is relatively common, since the underlying pathogenetic processes are still present, however graft loss due to recurrent disease appears to be rare [",
"    <a class=\"abstract\" href=\"UTD.htm?6/3/6202/abstract/84,86\">",
"     84,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the lack of definitive survival benefit over hemodialysis, patients should receive full explanation of the potential risks and benefits, to facilitate an informed decision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of sickle cell disease. The primary event leading to renal involvement appears to be sickling of erythrocytes in the vasa recta capillaries leading to microthrombotic infarction and extravasation of blood in the medulla. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal failure may ensue in over 10 percent of affected patients, but other clinically significant renal manifestations occur much more frequently. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Renal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with sickle cell nephropathy may be particularly vulnerable to develop acute tubular necrosis due to hemodynamic insults or toxins, acute pyelonephritis, and urinary tract obstruction. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of renal disease due to sickle cell disease is based on clinical manifestations and is largely a diagnosis of exclusion. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.) We recommend that all patients suspected of having sickle cell disease-associated renal disease have the following tests performed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urinalysis with microscopy, and quantitation of proteinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"       \"Urinalysis in the diagnosis of kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estimation of kidney function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal ultrasound. For patients with hematuria, a CT and IVP should also be obtained. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for hepatitis C and HIV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"       \"Epidemiology and transmission of hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"       \"Transfusion transmitted HIV infection and AIDS\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"       \"Transfusion transmitted bacterial infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a renal biopsy only if the urinalysis or course of renal failure and proteinuria suggest a glomerulonephritis.",
"     </li>",
"     <li>",
"      For the treatment of gross hematuria, we suggest conservative measures such as bed rest to avoid dislodging blood clots. For more severe cases, we suggest intravenous hydration using alkaline fluids. There are a number of different approaches for more persistent severe hematuria, none of which are well studied. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For delaying progression of CKD, we suggest use of ACE inhibitors or angiotensin II receptor blockers. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Progression of CKD and hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of anemia, we suggest that plasma hemoglobin concentration be maintained no higher than 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      with either blood transfusions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exogenous erythropoietin, and avoiding a hematocrit rise of greater than 1 to 2 percent per week. It is unclear whether exogenously administered erythropoietin should be routinely used in the management of anemia in patients with sickle cell disease and renal failure. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Anemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"       \"Overview of the management of sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link\">",
"       \"Specific therapies for sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with end-stage renal disease due to sickle cell disease can be treated with any of the modalities of renal replacement therapy. There does not appear to be a substantial survival benefit of one over the other, thus patients should receive full explanation of the potential risks and benefits to facilitate an informed decision. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'End-stage renal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/1\">",
"      Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/2\">",
"      Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/3\">",
"      Bruno D, Wigfall DR, Zimmerman SA, et al. Genitourinary complications of sickle cell disease. J Urol 2001; 166:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/4\">",
"      Powars DR, Elliott-Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med 1991; 115:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/5\">",
"      Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005; 84:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/6\">",
"      Powars DR, Hiti A, Ramicone E, et al. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol 2002; 70:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/7\">",
"      Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: the Bronx experience. Urology 2007; 70:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/8\">",
"      Odita JC, Ugbodaga CI, Okafor LA, et al. Urographic changes in homozygous sickle cell disease. Diagn Imaging 1983; 52:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/9\">",
"      McCall IW, Moule N, Desai P, Serjeant GR. Urographic findings in homozygous sickle cell disease. Radiology 1978; 126:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/10\">",
"      Sklar AH, Campbell H, Caruana RJ, et al. A population study of renal function in sickle cell anemia. Int J Artif Organs 1990; 13:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/11\">",
"      Falk RJ, Scheinman J, Phillips G, et al. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med 1992; 326:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/12\">",
"      Guasch A, Navarrete J, Nass K, Zayas CF. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol 2006; 17:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/13\">",
"      Sesso R, Almeida MA, Figueiredo MS, Bordin JO. Renal dysfunction in patients with sickle cell anemia or sickle cell trait. Braz J Med Biol Res 1998; 31:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/14\">",
"      Voskaridou E, Terpos E, Michail S, et al. Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. Kidney Int 2006; 69:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/15\">",
"      Abbott KC, Hypolite IO, Agodoa LY. Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002; 58:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/16\">",
"      Ashley-Koch AE, Okocha EC, Garrett ME, et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011; 155:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/17\">",
"      Scheinman JI. Tools to detect and modify sickle cell nephropathy. Kidney Int 2006; 69:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/18\">",
"      Derebail VK, Nachman PH, Key NS, et al. High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol 2010; 21:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/19\">",
"      Ojo AO, Govaerts TC, Schmouder RL, et al. Renal transplantation in end-stage sickle cell nephropathy. Transplantation 1999; 67:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/20\">",
"      Bhathena DB, Sondheimer JH. The glomerulopathy of homozygous sickle hemoglobin (SS) disease: morphology and pathogenesis. J Am Soc Nephrol 1991; 1:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/21\">",
"      Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int 2000; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/22\">",
"      Saborio P, Scheinman JI. Sickle cell nephropathy. J Am Soc Nephrol 1999; 10:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/23\">",
"      Maigne G, Ferlicot S, Galacteros F, et al. Glomerular lesions in patients with sickle cell disease. Medicine (Baltimore) 2010; 89:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/24\">",
"      Nasr SH, Markowitz GS, Sentman RL, D'Agati VD. Sickle cell disease, nephrotic syndrome, and renal failure. Kidney Int 2006; 69:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/25\">",
"      Serjeant GR. Sickle-cell disease. Lancet 1997; 350:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/26\">",
"      Bakir AA, Hathiwala SC, Ainis H, et al. Prognosis of the nephrotic syndrome in sickle glomerulopathy. A retrospective study. Am J Nephrol 1987; 7:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/27\">",
"      Wesson DE. The initiation and progression of sickle cell nephropathy. Kidney Int 2002; 61:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/28\">",
"      de Jong PE, Statius van Eps LW. Sickle cell nephropathy: new insights into its pathophysiology. Kidney Int 1985; 27:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/29\">",
"      Allon M, Lawson L, Eckman JR, et al. Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia. Kidney Int 1988; 34:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/30\">",
"      Bank N, Aynedjian HS, Qiu JH, et al. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int 1996; 50:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/31\">",
"      Haymann JP, Stankovic K, Levy P, et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clin J Am Soc Nephrol 2010; 5:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/32\">",
"      Tharaux PL, Hag&egrave;ge I, Placier S, et al. Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant 2005; 20:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/33\">",
"      De Paepe ME, Trudel M. The transgenic SAD mouse: a model of human sickle cell glomerulopathy. Kidney Int 1994; 46:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/34\">",
"      Schmitt F, Martinez F, Brillet G, et al. Early glomerular dysfunction in patients with sickle cell anemia. Am J Kidney Dis 1998; 32:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/35\">",
"      Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med 1990; 150:501.",
"     </a>",
"    </li>",
"    <li>",
"     Ter Maaten JC, Gans ROB, De Jong PE. In: Comprehensive Clinical Nephrology, eds. Johnson RJ, Feehally J, Elsevier. 2003; 665.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/37\">",
"      Domanovits H, Paulis M, Nikfardjam M, et al. Acute renal infarction. Clinical characteristics of 17 patients. Medicine (Baltimore) 1999; 78:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/38\">",
"      Lumerman JH, Hom D, Eiley D, Smith AD. Heightened suspicion and rapid evaluation with CT for early diagnosis of partial renal infarction. J Endourol 1999; 13:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/39\">",
"      Hatch FE, Culbertson JW, Diggs LW. Nature of the renal concentrating defect in sickle cell disease. J Clin Invest 1967; 46:336.",
"     </a>",
"    </li>",
"    <li>",
"     Scheinman JI. Sickle cell nephropathy. In: Pediatric Nephrology, eds. Holliday M, Barratt TM, Avner ED, Williams and Wilkins, 1994; 908.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/41\">",
"      Bayazit AK, Noyan A, Aldudak B, et al. Renal function in children with sickle cell anemia. Clin Nephrol 2002; 57:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/42\">",
"      Batlle D, Itsarayoungyuen K, Arruda JA, Kurtzman NA. Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. Am J Med 1982; 72:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/43\">",
"      De Jong PE, de Jong-van Den Berg LT, Statius van Eps LW. The tubular reabsorption of phosphate in sickle-cell nephropathy. Clin Sci Mol Med 1978; 55:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/44\">",
"      Alvarez O, Lopez-Mitnik G, Zilleruelo G. Short-term follow-up of patients with sickle cell disease and albuminuria. Pediatr Blood Cancer 2008; 50:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/45\">",
"      Marsenic O, Couloures KG, Wiley JM. Proteinuria in children with sickle cell disease. Nephrol Dial Transplant 2008; 23:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/46\">",
"      Sklar AH, Perez JC, Harp RJ, Caruana RJ. Acute renal failure in sickle cell anemia. Int J Artif Organs 1990; 13:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/47\">",
"      Audard V, Homs S, Habibi A, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant 2010; 25:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/48\">",
"      Thompson J, Reid M, Hambleton I, Serjeant GR. Albuminuria and renal function in homozygous sickle cell disease: observations from a cohort study. Arch Intern Med 2007; 167:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/49\">",
"      McPherson Yee M, Jabbar SF, Osunkwo I, et al. Chronic kidney disease and albuminuria in children with sickle cell disease. Clin J Am Soc Nephrol 2011; 6:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/50\">",
"      Yium J, Gabow P, Johnson A, et al. Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 1994; 4:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/51\">",
"      Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/52\">",
"      Swartz MA, Karth J, Schneider DT, et al. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology 2002; 60:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/53\">",
"      Avery RA, Harris JE, Davis CJ Jr, et al. Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer 1996; 78:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/54\">",
"      Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005; 44:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/55\">",
"      Lowe LH, Isuani BH, Heller RM, et al. Pediatric renal masses: Wilms tumor and beyond. Radiographics 2000; 20:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/56\">",
"      Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol 2003; 74:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/57\">",
"      Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Br J Haematol 2003; 120:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/58\">",
"      Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997; 89:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/59\">",
"      Hatch FE, Crowe LR, Miles DE, et al. Altered vascular reactivity in sickle hemoglobinopathy. A possible protective factor from hypertension. Am J Hypertens 1989; 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/60\">",
"      ter Maaten JC, Sern&eacute; EH, Bakker SJ, et al. Effects of insulin on glucose uptake and leg blood flow in patients with sickle cell disease and normal subjects. Metabolism 2001; 50:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/61\">",
"      Taori KB, Chaudhary RS, Attarde V, et al. Renal Doppler indices in sickle cell disease: early radiologic predictors of renovascular changes. AJR Am J Roentgenol 2008; 191:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/62\">",
"      Bergmann S, Zheng D, Barredo J, et al. Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease. J Pediatr Hematol Oncol 2006; 28:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/63\">",
"      Gurkan S, Scarponi KJ, Hotchkiss H, et al. Lactate dehydrogenase as a predictor of kidney involvement in patients with sickle cell anemia. Pediatr Nephrol 2010; 25:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/64\">",
"      Sundaram N, Bennett M, Wilhelm J, et al. Biomarkers for early detection of sickle nephropathy. Am J Hematol 2011; 86:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/65\">",
"      Knochel JP. Hematuria in sickle cell trait: the effect of intravenous administration of distilled water, urinary alkalinization, and diuresis. Arch Intern Med 1969; 123:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/66\">",
"      Duvic C, Bordier L, Hertig A, et al. [Macroscopic hematuria associated with sickle cell anemia trait: report of ten cases]. Rev Med Interne 2002; 23:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/67\">",
"      Pariser S, Katz A. Treatment of sickle cell trait hematuria with oral urea. J Urol 1994; 151:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/68\">",
"      Moudgil A, Kamil ES. Protracted, gross hematuria in sickle cell trait: response to multiple doses of 1-desamino-8-D-arginine vasopressin. Pediatr Nephrol 1996; 10:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/69\">",
"      Black WD, Hatch FE, Acchiardo S. Aminocaproic acid in prolonged hematuria of patients with sicklemia. Arch Intern Med 1976; 136:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/70\">",
"      Gabrovsky A, Aderinto A, Aderinto A, et al. Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. Pediatr Blood Cancer 2010; 54:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/71\">",
"      Bergin JJ. The complications of therapy with epsilon-aminocaproic acid. Med Clin North Am 1966; 50:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/72\">",
"      Herard A, Colin J, Youinou Y, et al. Massive gross hematuria in a sickle cell trait patient with renal papillary necrosis. Conservative approach using a balloon ureteral catheter to tamponade the papilla bleeding. Eur Urol 1998; 34:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/73\">",
"      Nagalla S, Ballas SK. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease (Review). Cochrane Database Syst Rev 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/74\">",
"      Foucan L, Bourhis V, Bangou J, et al. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med 1998; 104:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/75\">",
"      Aoki RY, Saad ST. Enalapril reduces the albuminuria of patients with sickle cell disease. Am J Med 1995; 98:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/76\">",
"      Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer 2005; 45:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/77\">",
"      Locatelli F, Aljama P, B&aacute;r&aacute;ny P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/78\">",
"      van Ypersele de Strihou, C. Should anaemia in subtypes of CRF patients be managed differently? Nephrol Dial Transplant 1999; 14 Suppl 2:ii37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/79\">",
"      Rodgers GP, Dover GJ, Uyesaka N, et al. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 1993; 328:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/80\">",
"      Dale GL, Alberio L. Is there a correlation between raised erythropoietin and thrombotic events in sickle-cell anaemia? Lancet 1998; 352:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/81\">",
"      Wong WY, Elliott-Mills D, Powars D. Renal failure in sickle cell anemia. Hematol Oncol Clin North Am 1996; 10:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/82\">",
"      Chatterjee SN. National study in natural history of renal allografts in sickle cell disease or trait: a second report. Transplant Proc 1987; 19:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/83\">",
"      Chatterjee SN. National study on natural history of renal allografts in sickle cell disease or trait. Nephron 1980; 25:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/84\">",
"      Montgomery R, Zibari G, Hill GS, Ratner LE. Renal transplantation in patients with sickle cell nephropathy. Transplantation 1994; 58:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/85\">",
"      Bleyer AJ, Donaldson LA, McIntosh M, Adams PL. Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis 2001; 37:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/3/6202/abstract/86\">",
"      Miner DJ, Jorkasky DK, Perloff LJ, et al. Recurrent sickle cell nephropathy in a transplanted kidney. Am J Kidney Dis 1987; 10:306.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7199 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-235EC14115-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6202=[""].join("\n");
var outline_f6_3_6202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RENAL PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RENAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renal infarction and papillary necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diminished concentrating ability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Abnormal proximal tubular function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Progressive renal failure and proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Renal medullary carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Early detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Progression of CKD and hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Dialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7199|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/12/43202\" title=\"diagnostic image 1\">",
"      RBF in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/15/2303\" title=\"diagnostic image 2\">",
"      Retrograde pyelogram in RPN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7199|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/48/29453\" title=\"figure 1\">",
"      Age at onset of renal dz in SSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/61/38879\" title=\"figure 2\">",
"      IVP in papillary necrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2886?source=related_link\">",
"      Chapter 9B: Renal water excretion and reabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27318?source=related_link\">",
"      Clinical manifestations and diagnosis of analgesic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11367?source=related_link\">",
"      Diagnosis and treatment of renal infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=related_link\">",
"      Overview of the treatment of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_3_6203="Rules for good sleep";
var content_f6_3_6203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ten basic rules for a good night's sleep",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Sleep only as much as you need to feel rested and then get out of bed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Keep a regular sleep schedule",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid forcing sleep",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exercise regularly for at least 20 minutes, preferably 4 to 5 hours before bedtime",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid caffeinated beverages after lunch",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid alcohol near bedtime: no \"night cap\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid smoking, especially in the evening",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Do not go to bed hungry",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adjust bedroom environment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Deal with your worries before bedtime",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6203=[""].join("\n");
var outline_f6_3_6203=null;
var title_f6_3_6204="Hypothalamic hormones";
var content_f6_3_6204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major hypothalamic hormones and their effect on anterior pituitary hormones",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Hypothalamic stimlatory hormones",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pituitary hormones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Corticotropin-releasing hormone - 41 amino acids; released from paraventricular neurons as well as supraoptic and arcuate nuclei and limbic system",
"       </td>",
"       <td>",
"        Adrenocorticotropic hormone - basophilic corticotrophs represent 20 percent of cells in anterior pituitary; ACTH is product of proopiomelanocortin (POMC) gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanocyte-stimulating hormone - alternate product of POMC gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endorphins - also products of POMC gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth hormone-releasing hormone - two forms, 40 and 44 amino acids",
"       </td>",
"       <td>",
"        Growth hormone - acidophilic somatotrophs represent 50 percent of cells in anterior pituitary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonadotropin-releasing hormone - 10 amino acids; mostly released from preoptic neurons",
"       </td>",
"       <td>",
"        Luteinizing hormone and follicle-stimulating hormone - gonadotrophs represent about 15 percent of anterior pituitary cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyrotropin-releasing hormone - three amino acids; released from anterior hypothalamic area",
"       </td>",
"       <td>",
"        Thyroid-stimulating hormone - thyrotropes represent about&nbsp;5 percent of anterior pituitary cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolactin-releasing factors - include serotonin, acetylcholine, opiates, and estrogens",
"       </td>",
"       <td>",
"        Prolactin - lactotrophs represent 10 to 30 percent of anterior pituitary cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Hypothalamic inhibitory hormones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatostatin - 14 amino acids",
"       </td>",
"       <td>",
"        Inhibits the release of growth hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolactin-inhibiting factors - includes dopamine",
"       </td>",
"       <td>",
"        Major prolactin control is inhibitory",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6204=[""].join("\n");
var outline_f6_3_6204=null;
var title_f6_3_6205="Asperger disorder DDx";
var content_f6_3_6205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of Asperger disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Features that may help to distinguish the condition from Asperger disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Pervasive developmental disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autistic disorder",
"       </td>",
"       <td>",
"        Significant abnormalities in language, play, and cognitive skills; onset before age three years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High-functioning autism (HFA)",
"       </td>",
"       <td>",
"        Significant abnormalities in language, play, and cognitive skills; onset of symptoms before age three years, but diagnosis may be made later than for autistic disorder. The difference between HFA and Asperger disorder is an area of controversy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pervasive developmental disorder not otherwise specified",
"       </td>",
"       <td>",
"        Some, but not all, of the criteria for autistic disorder are present (may have late age of presentation, or atypical or subthreshold symptoms; or may meet only two of the three criteria for autistic disorder)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rett disorder",
"       </td>",
"       <td>",
"        Female predominance; head growth deceleration; loss of skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Childhood disintegrative disorder",
"       </td>",
"       <td>",
"        Marked intellectual disability and language impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Attention deficit hyperactivity disorder*",
"       </td>",
"       <td>",
"        Lack of impairment in social interaction; lack of restricted patterns of behavior; normal pragmatic language skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schizophrenia*",
"       </td>",
"       <td>",
"        Hallucinations; delusions; disorganized speech",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selective mutism",
"       </td>",
"       <td>",
"        Lack of impairment in social interaction; normal ability for communication in some settings; lack of restricted patterns of behavior and stereotypies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Language disorder (expressive or mixed receptive-expressive)",
"       </td>",
"       <td>",
"        Normal social skills; lack of restricted patterns of behavior; lack of stereotypies; onset before age three years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonverbal learning disorder*",
"       </td>",
"       <td>",
"        Less impairment in social skills and pragmatic language than for individuals on the autism spectrum; verbal skills typically stronger than nonverbal skills; do not show the same repetitive behaviors and restricted interests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obsessive compulsive disorder*",
"       </td>",
"       <td>",
"        Normal social skills; normal pragmatic language; restricted/repetitive behaviors are a source of anxiety rather than a pleasure (as they are in autistic disorder or Asperger disorder)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Social phobia/anxiety*",
"       </td>",
"       <td>",
"        Lack of pervasive impairments in social development; lack of circumscribed interests; subjective distress about social interactions and about specific situations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal social awkwardness",
"       </td>",
"       <td>",
"        Normal age-appropriate interests and hobbies; normal pragmatic language skills",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May occur comorbidly with Asperger disorder.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Asperger's disorder. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;). American Psychiatric Association, Arlington, VA 2000. p.80.",
"       </li>",
"       <li>",
"        Johnson CP, Myers SM. Autism spectrum disorders. In: Developmental-Behavioral Pediatrics. Evidence and Practice. Wolraich ML, Drotar DD, Dworkin PH, Perrin EC (Eds). Mosby Elsevier, Philadelphia 2008. p.519.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6205=[""].join("\n");
var outline_f6_3_6205=null;
var title_f6_3_6206="Longitudinal relaxation in MRI";
var content_f6_3_6206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53513%7EPULM%2F74502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53513%7EPULM%2F74502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal relaxation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 199px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Evolution of magnetization after a 180&deg; radiofrequency excitation. Magnetization is flipped 180&deg; at time zero (t=0). Magnetization relaxes toward equilibrium as energy is lost. Magnetization recovery is 63 percent complete at time t=T1 and 100 percent complete at time t&gt;&gt;T1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Rate of recovery during longitudinal relaxation in MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recovery of the longitudinal component of magnetization to its equilibrium value is exponential with a time constant T",
"    <sub>",
"     1",
"    </sub>",
"    . T",
"    <sub>",
"     1",
"    </sub>",
"    depends upon field strength, temperature, and tissue composition.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6206=[""].join("\n");
var outline_f6_3_6206=null;
var title_f6_3_6207="Maisonneuve stress view";
var content_f6_3_6207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Maisonneuve stress view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stress radiographs may reveal injuries not apparent on standard views. In the x-ray above, the application of an external rotation force to the foot reveals a widening of the medial tibiotalar space (arrow). This is indicative of a sprain or rupture of the tibiofibular syndesmosis. There may also be an associated fracture&nbsp;(Maisonneuve fracture) of the proximal fibula (not seen on this view).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_3_6207=[""].join("\n");
var outline_f6_3_6207=null;
